001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015
CLINICAL TRIAL PROTO COL                                                                                                     
TITLE PAGE
Document Number: c03495745 -05
EudraCT No.: 2015-003148-38
BI Trial No.:   1199.227
BI Investigational 
Product(s):   Ofev®, nintedanib
Title:A 12- week, double blind, randomis ed, placebo controlled, parallel 
group trial followed by a single active arm phase of 40 weeks 
evaluating the effect of oral nintedanib 150 mg twice daily on change 
in biomarkers of extracellular matrix (ECM) turnover in patients with 
idiopathic pulmonary fibrosis (IPF) and limited forced vital capa city 
(FVC) impairment .
Brief Title:Effect of nintedanib on biomarkers of ECM turnover in patients with 
IPF and limited FVC impairment
Clinical Phase: IV
Trial Clinical 
Monitor:
Phone:  Fax: 
Coordinating 
Investigator:   
  
  ,
  
  
   Phone:  Fax: 
Status:    Final Protocol ( Revised Proto col (based on global amendment 4))
Version and Date: Version: 5.0 Date: 09Jul 2018
Page 1 of 95
Proprietary confidential information .
2018 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not -in full or in part -be passed on, reproduced, published or otherwise used without prior written permission.

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 2of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015CLINICAL TRIAL PROTO COL SYNOPSIS
Nam e of company: Boehringer Ingelheim 
Nam e of finished product: Ofev®
Nam e of active ingredient: Nintedanib
Protocol date:
11Feb 2016Trial number:
1199.227Revision date:
09Jul2018
Title of trial: A12-week, double blind, randomis ed, placebo controlled, parallel group trial 
followed by a single active arm phase of 40 w eeks evaluating the effect of oral 
nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix 
(ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited
forced vital capacity (FVC) impairm ent.
Coordinating
Investigator:
Trial site(s): Multi -centre, multi -national trial
Clinical phase: IV
Objective(s): To investigate the effect of nintedanib on various extracellular matrix (ECM) 
turnover biomarker s and the predictive value of change in those ECM biom arker s 
on disease progression.
Methodology: 12-week randomis ed, double blind, parallel group ,placebo controlled phase 
followed by a single active arm phase of 40 w eeks
No. of patients: 
~490 enrolled (screened) patients
total entered:
~350entered (randomised) patients 
each treatm ent: Nintedanib: 117
Placebo: 233*
*applicable to 12 -week randomis ed part of the trial 
Diagnosis :Idiopat hic Pulmonary Fibrosis (IPF)
Main criteria
for inclusion:Male or female patients aged ≥40 years at Visit 1 (screening); IPF diagnosis based 
upon ATS/ERS/JRS/ALAT 2011 guideline within 3 yearsof Visit 0 ; HRCT 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 3of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015Nam e of company: Boehringer Ingelheim 
Nam e of finished product: Ofev®
Nam e of active ingredient: Nintedanib
Protocol date:
11Feb 2016Trial number:
1199.227Revision date:
09Jul2018
perfo rmed within 18 months of Visit 0; confirmation of diagnosis by central 
review of chest HRCT andsurgical lung biopsy (later if available) prior to 
randomis ation; FVC ≥ 80% predicted of normal at Visit 1 (screening) 
Test product(s):
Nintedanib
dose:300 mg daily (150 mg bid) w ith possibility to reduce total daily dose to 200 mg 
(100 mg bid) to manage adverse events (AEs)
mode of 
admin istration : oral 
Comparator products:
Placebo matching Nintedanib
dose:
Not applicable
mode of 
admin istration : oral 
Duration of treatm ent: 52 w eeks 
EndpointsPrimary Endpoint:
Rate of change (slope) in bloo d CRPM from baseline to week 12
Key Secondary Endpoint:
Proportion of patients with disease progression as defined by absolute 
FVC (% predicted) decline ≥10% or death until week 52
Secondary Endpoints:
Rate of change (slope) in blood C1M from baseline to w eek 12
Rate of change (slope) in blood C3M from baseline to w eek 12
Further Endpoints (selected):
 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 4of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015Nam e of company: Boehringer Ingelheim 
Nam e of finished product: Ofev®
Nam e of active ingredient: Nintedanib
Protocol date:
11Feb 2016Trial number:
1199.227Revision date:
09Jul2018
 
 
Safety criteria : Adverse events (especially SAE and other significant AE) , physical examination, 
weight measurements , 12 lead electrocardiogram , vital si gns and laboratory 
evaluations.
Statistical m ethods: Random coefficient regression m odels for continuous endpoints, Log rank tests, 
Kaplan -Meier plots and Cox regressions for time to event endpoints, logistic 
regression models or other appropriate methods for binary endpoints

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 5of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 6of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Informed consent should be obtained before any study procedure including the shipment of the HRCT image and 
biopsy sample (if available) for central review. 
2. At visit 1, height measurement s hould be included.
3. PK samples will be taken at Visits 3, 6 and 10just prior to drug administration. Patients will be provided with a PK 
card/diary to support the record of the exact clock time of medication intake three days prior to PK sampling .
4. Blood sample sfor serum banking and pharmacogenetics may be drawn from all randomised patients who received at 
least one dose of trial medication and who gave a separate informed consent. Pa tients will be asked to participate in 
the biobanking subset , i.e. pharmacogenetic and serum biobanking . Still, the participation isvoluntarily and not a pre -
requisite for participation in the trial. The single pharmacogenetic sample will be drawn at Visit 2 or at any other 
subsequent visit after randomisation. Serum ban king samples shall be drawn as per Flow Chart.
5. SGRQ, UCSD -SOBQ : the first procedure at the clinic .
6. Patient diary will be issued at Visit 2 and will be reviewed at each clinic visit up until Visit 10 . Content to be discussed 
and reviewed by the site staff as it pertains to AEs and concomitant therapy and times of drug intake three days prior 
to the PK sampling.
7. Including acute IPF exacerbations
8. Patients who prematurely discontinue from the trial and don’t accep t to attend all planned visits will be contacted for 
vital status collection at week 52.
9. No fasting required .
10. If performance compliance is below 80% or as deemed necessary by the site.

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 7of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan201511. To be performed after pre-dose PK sample (if applicable) and after current visit exams .
12. Perform only if abnormal or findings needi ng follow -up recorded at Visit 10.
13. Visit 1 should only be conducted after IPF diagnosis has been confirmed by central review. 
14. In case of dose change of nintedanib (reduc tion or re -escalation), dose adjustment visit must be conducted to allow 
dispensing of new medication kit.
15. Early e nd of treatment visit to be completed for all patients who withdraw or discontin uestudy treatment prematurely .
Patients who prematurely d iscontinue treatment will then be invited to attend all visits as planned until week 52 (Visit 
10).
16. Screening period (period between Visit 1 and 2) should last 14 days (2 weeks). The screening period may be 
prolonged by additional 2 week for anyreasons, i.e. total 28 days (4 weeks). Eligible patients can be randomis ed once 
central lab results have been received and are found to be consistent with eligibility criteria.  
17. 4 days prior to planned PK sampling site should preferably contact the patient to record times of drug intake within 
patient diary. Patient should record times of drug intake three days prior to the PK sampling.
18. In women of childbearing potential.
19. Applicable only if patient doesn’t accept to attend remaining schedule d visits. 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 8of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015TABLE OF CONTENTS
CLINICAL TRIAL PROTO COL.......................................................................................... 1
TITLE PAGE ........................................................................................................................... 1
CLINICAL TRIAL PROTO COL SYNOPSIS ..................................................................... 2
TABLE OF CONTENTS ........................................................................................................ 8
ABBREVIATIONS ................................................................................................................ 12
1. INTRODUCTION ................................
............................................................... 15
MEDICAL BACKGROUND ............................................................................. 15 1.1
DRUG PROFILE ................................................................................................ 16 1.2
2. RATIONALE, OBJECTIVE S, AND BENEFIT -RISK ASSESSMENT .....19
RATIONALE FOR PERFOR MING THE TRIAL ......................................... 19 2.1
TRIAL OBJECTIVES ........................................................................................ 20 2.2
BENEFIT - RISK ASSESSMENT ................................ ..................................... 20 2.3
3. DESCRIPTION OF DESIG N AND TRIAL POPULATI ON......................... 22
OVERALL TRIAL DESIGN AND PLAN ....................................................... 22 3.1
3.1.1 Administrative structure of the trial ................................................................. 23
DISCUSSION OF TRIAL DESIGN, INCLUDING TH E CHOICE OF 3.2
CONTROL GROUP(S) ...................................................................................... 25
SELECTION OF TRIAL P OPULATION ....................................................... 26 3.3
3.3.1 Main diagnosis for trial entry ............................................................................ 26
3.3.2 Inclusion criteria ................................................................................................. 26
3.3.3 Exclusion criteria ................................................................................................ 27
3.3.4 Removal of patients from therapy or assessments........................................... 29
Removal of individual patients ............................................................................. 29 3.3.4.1
Discontinuation of the trial by  the sponsor ........................................................... 30 3.3.4.2
4. TREATMENTS ................................
................................................................... 31
TREATMENTS TO BE ADM INISTERED ..................................................... 31 4.1
4.1.1 Identity of BI investigational product(s) and comparato r product(s) ........... 31
4.1.2 Method of assigning patients to treatment groups ........................................... 32
4.1.3 Selection of doses in the trial .............................................................................. 33
4.1.4 Drug assignment and administration of doses for each patient ...................... 33
4.1.5 Blinding and procedures for unblinding ........................................................... 35
Blinding................................................................................................................. 35 4.1.5.1
Unblinding and breaking the code ........................................................................ 35 4.1.5.2
4.1.6 Packaging, labelling, and re- supply ................................................................... 35
4.1.7 Storage conditions ............................................................................................... 35
4.1.8 Drug accountability ................................
............................................................. 36

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 9of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015CONCOMITANT THERAPY, RESTRICTIONS, AND RE SCUE  4.2
TREATMENT ..................................................................................................... 36
4.2.1 Rescue medication, emergency procedures , and additional treatment(s) ..... 36
Recommendations for managing adverse events (exceptions include diarrhea and 4.2.1.1
liver enzy me elevations) ....................................................................................... 36
Recommendations for management of diarrhea ................................................... 37 4.2.1.2
Recommendations for management of liver enz yme elevation ............................ 39 4.2.1.3
Management of acute IPF exacerbations and acute deteriorations ....................... 40 4.2.1.4
4.2.2 Restrictions .......................................................................................................... 40
Restrictions regarding concomitant treatment ...................................................... 40 4.2.2.1
Restrictions on diet and life sty le.......................................................................... 41 4.2.2.2
Restrictions regarding women of childbearing potential ...................................... 42 4.2.2.3
TREATMENT COMPLIANCE ........................................................................ 42 4.3
5. VARIABLES AND THEIR ASSESSMENT .................................................... 43
TRIAL ENDPOINTS ................................
.......................................................... 43 5.1
5.1.1 Primary Endpoint ............................................................................................... 43
5.1.2 Secondary Endpoints .......................................................................................... 43
ASSESSMENT OF EFFICA CY................................
........................................ 44 5.2
ASSESSMENT OF SAFETY ............................................................................. 45 5.3
5.3.1 Physical examination .......................................................................................... 45
5.3.2 Vital Signs ............................................................................................................ 46
5.3.3 Safety laboratory parameters ............................................................................ 46
5.3.4 Electrocardiogram .............................................................................................. 46
5.3.5 Other safety parameters
..................................................................................... 47
5.3.6 Assessment of adverse events ............................................................................. 47
Definitions of AEs ................................................................................................ 47 5.3.6.1
5.3.7 Adverse event collection and reporting ............................................................. 50
 
ASSESSMENT OF EXPLOR ATORY BIOMARKER(S)
.............................. 53 5.5
5.5.1 Analytical determinations .................................................................................. 54
5.5.2 Biobanking ................................................................
........................................... 54
OTHER ASSESSMENTS ................................................................................... 55 5.6
APPROPRIATENESS OF M EASUREMENTS .............................................. 55 5.7
6. INVESTIGATIONAL PLAN ............................................................................. 56
VISIT SCHEDULE ............................................................................................. 56 6.1
DETAILS OF TRIAL PRO CEDURES AT SELECTED VISITS ................. 57 6.2
6.2.1 Screening and run -in period(s) .......................................................................... 57
6.2.2 Treatment period(s) ............................................................................................ 58
6.2.3 Follow Up Period and Trial Completion ........................................................... 62

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 10of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan20157. STATISTICAL METH ODS AND DETERMINATIO N OF SAMPLE SIZE
............................................................................................................................... 64
STATISTICAL DESIGN - MODEL ................................................................. 64 7.1
NULL AND ALTERNATIVE HYPOTHESES ............................................... 64 7.2
PLANNED ANALYSES ..................................................................................... 64 7.3
7.3.1 Primary endpoint analyses ................................................................................. 65
7.3.2 Secondary endpoint analyses ............................................................................. 65
7.3.4 Safety analyses ..................................................................................................... 66
INTERIM ANALYSES ................................
...................................................... 67 7.4
HANDLING OF MISSING DATA ................................................................... 67 7.5
7.5.1 Efficacy endpoints ............................................................................................... 67
7.5.2 Safety endpoints ................................................................
.................................. 68
RANDOMISATION ........................................................................................... 68 7.6
DETERMINATION OF SAM PLE SIZE ......................................................... 68 7.7
8. INFORMED CONSENT, DA TA PROTECTION, TRIAL RECORDS ........ 71
TRIAL APPROVAL, PATI ENT INFORMATION, AND INFORMED 8.1
CONSENT ........................................................................................................... 71
DATA QUALITY ASSURANCE ...................................................................... 72 8.2
RECORDS ................................................................
........................................... 72 8.3
8.3.1 Source documents ............................................................................................... 73
8.3.2 Direct access to source data and documents..................................................... 73
8.3.3 Storage period of records ................................
................................................... 73
LISTEDNESS AND EXPEDITED REPORTING OF AD VERSE EVE NTS 73 8.4
8.4.1 Listedness ............................................................................................................. 73
8.4.2 Expedited reporting ................................
............................................................ 74
STATEMENT OF CONFIDE NTIALITY ........................................................ 74 8.5
END OF TRIAL ................................................................
.................................. 74 8.6
PROTOCOL VIOLATIONS ............................................................................. 74 8.7
COMPENSATION AVAILAB LE TO THE PATIENT IN THE EVENT OF 8.8
TRIAL RELATED INJURY .............................................................................. 74
9. REFERENCES .................................................................................................... 75
PUBLISHED REFERENCES ............................................................................ 75 9.1
UNPUBLISHED REFERENC ES...................................................................... 79 9.2
10. APPENDICES ................................
..................................................................... 80
CRITERIA FOR HRCT/BI OPSY CENTRAL ................................................ 80 10.1
CREATININE CLEARANCE ........................................................................... 80 10.2
DLCO ................................
................................................................................... 91 10.5

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 11of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan201511. DESCRIPTION OF GLOBA L AMENDMENT(S) ......................................... 92
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 12of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015ABBREVIATIONS
AE Adverse Event
AESI
ALAT
ALP
ALT
AST
ATP
ATSAdverse Event of Special Interest
Latin American Thoracic Association
Alkaline phosphatase
Alanine transaminase
Aspartate aminotransferase
Adenosine triphosphate
American Thoracic Society
AUC
b.i.d.Area under the Curve
bis in die (twice dail y dosing)
BI Boehringer Ingelheim
BIRDS
BS
C1M
C3M
CABoehringer Ingelheim Regulatory  Documents for Submission
Biomarker Set
Collagen 1 degraded by  MMP -2/9/13
Collagen 3 degraded b y MMP -9
Competent Authority
CI Confidence Interval
CML
CNSLocal Clinical Monitor 
Central Nervous S ystem
CRA Clinical Research Associate
CRF
CRO
CRPMCase Report Form
Clinical Research Organisation
C-reactive protein degraded by MMP -1/8
CTCAE Common Terminology  Criteria for Adverse Events
CTP Clinical Trial Protocol
CTR
DDI
DEDP
DILI
DLCOClinical Trial Report
Drug-drug interaction
Drug exposure during pregnancy
Drug induced liver injury
Carbon monoxide diffusing capacity
DMC
DNAData Monitoring Committee
Deox yribonucleic Acid
eCRF
ePRO
ECG
ECMElectronic Case Report Form
Electronic Patient Reported Outcome
Electrocardiogram
Extracellular matrix
EDC
EDTA
EOTElectronic Data Capture
Ethy lendiamintetraacetate
End of treatment

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 13of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015ERS European Respiratory  Society
EudraCT European Clinical Trials Database
FAS Full Anal ysis Set
FC
FDA
FGFR
FVCFlow Chart
Food and Drug Administration
Fibroblast growth factor/receptor
Forced vital capacit y
GCP
GGT
GI
ß-HCGGood Clinical Practice
Gamma -glutam yl transferase
Gastrointestinal
β -human Chorionic Gonadotropin  
HPC
HRCTHuman Pharmacology  Center
High Resolution Computer Tomograph y
IB
ICH GCPInvestigator’s Brochure
International Conference on Harmonisation Good Clinical Practice
IEC
INR
IPFIndependent Ethics Committee
International normalised ratio
Idiopathic pulmonary  fibrosis
IRB Institutional Review Board
IRT Interactive Response Technology
ISF Investigator Site File
i.v. intravenous
IVRS Interactive Voice Response Sy stem
IWRS
JRS
LC-MS/MS
LDHInteractive Web -based Response Sy stem
Japanese Respiratory  Society
Liquid chromatograph y
-tandem mass spectrometry
Lactate dehy drogenase
LoEE List of Essential Element 
MedDRA
MMPsMedical Dictionary  for Drug Regulatory  Activities
Metalloproteinases
MMRM Mixed Effects Model for Repeated Measures
MST
N/A
NAC
nRTKsMedical Sub team
Not Applicable
n-acetylcysteine
N
on-receptor t yrosine kinases
OPU Operative Unit
p.o. per os (oral)
PCC
PD
PDGFRProtocol Challenge Committee
Pharmacod ynamic/ Pharmacod ynamics
Platelet derived growth factor/receptor

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 14of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015PFT
PG
PK
PKS
PT
PTTPulmonary  Function Test
Pharmacogenetics
Pharmacokinetic Set
Pharmacokinetic/ Pharmacokinetics
Prothrombin time 
Partial thromboplastin time
q.d.
RDCquaque die (once a day )
Remote Data Capture
REP
RS
RTKsResidual effect period, after the last dose of medication with measureable 
drug levels or pharmacodynamic effects still likely to be present   
Randomised Set
Receptor t yrosine kinases
SAE Serious Adverse Event
s.c.
SGRQ
SOPSubcutaneous
St.George’s Respiratory  Questio nnaire
Standard Operating Procedure
SPC
SP-D
SpO2Summary  of Product Characteristics
Surfactant Associated Protein -D
Oxygen Saturation
TCM Trial Clinical Monitor
TDMAP Trial Data Management and Anal ysis Plan
t.i.d. ter in die (3 times a day )
TMF Trial Master File
TMW
TSTrial Medical Writer
Treated Set
TSAP
TSH
UIP
ULN
UCSD -SOBQ
VEGFRTrial Statistical Analy sis Plan
Thyroid stimulating hormone
Usual Interstitial Pneumonia
Upper Limit Normal 
UCSD Shortness of Breath Questionnaire
Vascular endothelial growth factor/receptor

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 15of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan20151. INTRODUCTION
MEDICAL BACKGROUND 1.1
Idiopathic pulmonary  fibrosis (I PF) is a rare disease of unknown aetiology  that is 
characterized b y progressive fibrosis of the interstitium of the lung, leading to decreasing 
lung volume and progressive pulmonary  insufficiency [P11-07084].
The course of the disease in individual patients is variable : some patients progress rapidly ,
others have periods of relative stability  punctuated by  acute exacerbations and others progress 
relativel y slowly. Acute exacerbations of IPF are events of respiratory deterioration of 
unidentified cause that occur in 5 –10% of patients annually  and are associated with a very  
poor outcome [R12-2786]. 
IPF is most prevalent in middle aged and elderl y patients, and usually  presents between the 
ages of 40 and 70 years.The median life expectancy  in IPF patients after diagnosis is 2 to 3 
years[P11-07084].
The latest update on clinical practice guideline for the treatment of IPF, jointly  issued in 2015
by the American Thoracic Society  (ATS), European Respiratory  Societ y (ERS), Japanese 
Respiratory  Societ y (JRS) and Latin American Thoracic Association (ALAT) has provided a 
conditional recommendation for treatment with nintedanib or pirfenidone for the majority  of 
IPF patients, taking into account individual patient values and preferences [P15 -07362] . 
Conventional I PF treatments such as n-acetylcysteine (NAC), corticosteroids, 
cyclophosphamide, cy closporine and azathioprine are not approved treatments for I PF, and 
their efficacy  is que stionable or even harmful [ P15-07362; P12-06085; P14-07665]. Non-
pharmacological therapies such as pulmonary  rehabilitation and long -term oxy gen therap y 
are recommended for some patients, but their efficacy  in patien ts with IPF has not been 
established. Lung transplant has been shown to positively  impact survival in patients w ith 
IPF. [R11-5086; R12-2785]. Although t he number of patients transplanted due to I PF has 
increased steadil y over the last y ears, the scarce availability  of donor organs , as well as the 
comorbidities and advanced age preclude man y patients from referral to lung transplant [R12-
3676 ; R12-3474].
Pirfenidone , a compound which demonstrated anti- fibrotic activit y in non -clinical models, 
was first licensed in Japan in 2008 based on two local trials which showed a reduce d decline 
of vital capacity under treatment with the compound [ R06-2070; R10-4316 ].In the
international Phase III CAPACI TY program, pirfenidone demonstrated efficacy  on the 
primary  FVC lung function endpoint in only  one of two confirmatory  trials [ R11- 4827]. The
additional confirmatory  ASCEND P hase III trial requested b y FDA met the primary  endpoint 
of change from baseline FVC % predicted [ R14-2103]. Pirfenidone isalsolicensed since 
February  2011 for the treatment of mild to moderate I PF in the E uropean Union and since 
October 2014 
for the treatment of I PF in the U nited States of A merica . It is also licensed in
several other countries .
Nintedanib is a small molecule in tracellular t yrosine kinase inhibitor which has demonstrated 
anti-fibrotic and anti-inflammatory  activity  in preclinical models [ P08-08684 ; P14-02860]. 
The t wo replicate Phase III INPULSIS trials an d the Phase II TOMORROW trial consistently  
showed positive results for the efficacy  of nintedanib 150 mg twice daily  versus placebo in 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 16of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015patients with I PF. Both INPUL SIS trials showed that nintedanib reduced the annual rate of 
decline in FVC (mL/ year) by  approximately  50%, consistent wi th slowing disease 
progression [ P14-07514; P11-11216] . Based on these three clinical trials, nintedanib was 
approved for the treatment of I PF in the USA in October 2014, in the E uropean U nion in 
January  2015 and in Japan in July  2015. As of 20 October 2015, nintedanib has also been 
approved in Canada, Switzerland, Russia, Australia, Chile, Ecuador and Taiwan and it has 
been submitted for marketing authorization in other countries across the world.
Although nintedanib and pirfenidone can be considered a standard of care for patients 
diagnosed with I PF, it remains unclear when to start and when to stop treatment with either of 
the drugs, given the unpredictability  of clinical course in the individual patient as well as the 
lack of biomarkers to inform patient management and therapeutic response.
With the introduction of nintedanib in the treatment algorithm of IPF, there is an additional 
need to further characterize its profile in patients at an earl y disease stage, i.e. in patients with  
limited lung volume impairment, an d to address the question when to start treatment in these 
patients. Currently , many phy sicians apply  a wait and watch strategy  for these patients as 
there are no markers to predict the individual course in a given patient or response to 
treatment which ma y result in a delay  of treatment initiation. Identify ing biomarkers to 
predict the clinical course and benefits of therapy  for a given patient earl y in the course of the 
disease remains one of themost urgent and relevant challenges in patient management
DRUG PROFILE 1.2
Nintedanib is a small molecule that inhibits a distinct spectrum of receptor ty rosine kinases 
(RTKs) and non- receptor ty rosine kinases (nRTKs) at pharmacologicall y relevant 
concentrations. Among them, FGFR (fibroblast growth factor/receptor), PDGFR (platelet 
derived growth factor/receptor) and VEGFR (vascular endothelial growth factor /receptor) 
have been implicated in IPF pathogenesis. Nintedanib binds competitively  to the adenosine 
triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signalling 
which is crucial for the proliferation, migration, and transfo rmation of fibroblasts 
representing essential mechanisms of the IPF pathology  [P08-08684; P14-02860]. 
A soft gelatin capsule formulation of nintedanib is used in humans. Maximum plasma 
concentrations occur between 2 -4 hours after oral administration. Steady  state is reached at 
the latest within one week of dosing. After food intake, a trend towards an increased s ystemic 
exposure (around 15 to 20%) and a delay ed absorption was observed compared to 
administration under fasted conditions. Nintedanib is recommended to be taken with food. 
Nintedanib is preferentially  distributed in plasma ,with a blood to plasma ratio of 0.87; the 
terminal half -life is in t he range of 7 to 19 h. The absolute bioavailability  of nintedanib was 
slightly  below 5%. Nintedanib is mainly  eliminated via faeces.
Co-administration of nintedanib with the P- glycoprotein (P -gp) inhibitor ketoconazole 
increased exposure to nintedanib by  60-70% based on area under the curve (AUC) and by  
80% based on a maximum measured concentration of the anal yte in plasma (Cmax) in a 
dedicated drug -drug interaction (DDI) study . Patients taking potent P -gp inhibitors (e.g 
ketoconazole, ery throm ycin or cy closporine) should be monitored closel y for tolerability of 
nintedanib. 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 17of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015In a DDI stud y with the P -gp inducer rifampicin, exposure to nintedanib decreased to 50.3% 
based on AUC and to 60.3% based on Cmax upon co- administration compared to 
administration of ni ntedanib alone. Since potent P -gp inducers may  decrease exposure to 
nintedanib, selection of alternat ive treatment with no or minimal P -gp induction should be 
considered. 
The clinical efficacy  of nintedanib has been studied in over 1400 patients with I PF in one 
phase II dose finding study  (TOMORROW) including four different doses of nintedanib, and 
two replicate phase III (INPUL SIS 1 and 2) trials. These were randomis ed, double -blind, 
placebo
-controlled studies comparing treatment with nintedanib twice dai ly to placebo for 52 
weeks. A statisticall y significant reduction in the annual rate of decline of FVC (in mL) was 
demonstrated in patients receiving nintedanib 150 mg bid compared to patients receiving 
placebo. The treatment effect on FVC was consistent i n all 3 studies, i.e. a relative reduction 
of approximately  50% between nintedanib and placebo. Furthermore ,nintedanib 150 mg bid 
significantl y reduced the risk of first acute exacerbation compared with placebo in 
INPULSIS -2 and in the TOMORROW trial, and reduced the risk of adjudicated 
confirmed/suspected acute exacerbations by 68% in a pre -specified sensitivity  anal ysis of  
pooled data from the INPULSIS®trials, supporting the effect of nintedanib on slowing 
disease progression [ P14-07514; P11- 11216].
The safet y profile of nintedanib has been investigated comprehensivel y. The proportion of 
patients with serious adverse events was similar in the nintedanib and placebo groups. 
The risks of treatment with nintedanib in adult patients are primarily  related to the 
gastrointestinal tract (nausea, vomiting, diarrhea , abdominal pain) and to increases in liver 
enzy mes aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline 
phosphatase (ALP), gamma -glutam yl transferase (GGT) and bilirubin. The most frequently  
reported adverse event was diarrhea which was mild to moderate in intensity for the vast 
majority  of patients and lead to treatment discontinuation in less than five percent of patients 
treated with nintedanib. Weight decrease and decreased appetite have also frequentl y been 
reported in studies with nintedanib. 
Potential risks of nintedanib treatment also include arterial h ypertension, GI perforations, 
thromboembolism and bleeding. Patients treated with full -dose anticoagulation or at known 
risk for bleeding were excluded from the INPULSIS trials . This has led to recommendations 
stating that patients at known risk for bleeding should be treated with nintedanib only if the 
anticipated benefit outweighs the potential risk. Although cardiac disorder AEs were 
balanced between the nintedanib and placebo groups, a higher proportion of patients in the 
nintedanib groups had my
ocardial infarctions. Conversel y, a lower p roportion of patients in 
the nintedanib groups had other ischemic heart disease. ‘Other ischemic heart disease’ was a 
pre-defined category  including terms such as coronary  artery  disease, angina pectoris, 
coronary  angioplasty , coronary  artery  stenosis, myocardial ischemia, coronary  artery  stent 
insertion, electrocardiogram (ECG) ST segment depression. The clinical significance of this 
finding is unknown, and further observation is needed.
For patients finalizing the 52 week stud y treatment in the TOMORROW a nd INPUL SIS 
trials, participation in open label extension trials (1199.35 and 1199.33) was offered. Long 
term treatment in these still ongoing open label extension trials confirm the safet y profile 
observed in the phase II and III trials [P15 -09876] .
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 18of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015Nintedanib has also demonstrated efficacy  and tolerable safet y in patients with non -small cell 
lung cancer who failed first line treatment [P11 -00203], as well as in patients with advanced 
renal cell can cer [P13 -06268] , ovarian cancer [P11 -10116] and hepatocellular carcinoma 
[P13 -12693] . Furthermore, nintedanib is also being investi gated in other oncological 
indications, such as mesothelioma [P14 -08020] .
For a more detailed description of the drug profile ,refer to the current Investigator’s 
Brochure (IB)which is included in the Investigator Site File ( ISF).
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 19of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan20152. RATIONALE, OBJECTIVE S, AND BENEF IT -RISK 
ASSESSMENT
RATIONALE FOR PERFOR MING THE TRIAL 2.1
Until recentl y, IPF was essentially an untreatable disease. With the availability  of specific 
antifibrotic drugs like nintedanib and pirfenidone , a major advance in the management of IPF 
has been achieved. However, based on the heterogeneity of disease progression and the lack 
of validated prognostic biomarkers, the clinical course in an individual patient remains
unpredictable which is also true for the individual response to treatments.
Retrospective studies have identified several factors at a single point in time (baseline 
factors) or over time (longitudinal factors) that are associated with increased mortality  in IPF. 
Change in ph ysiologic 
measures over time, such as a bsolute decline in FVC % predicted 
normal by  10% or more, are associated with reduced survival; This association is only seen 
after a minimum of 6-12 months [R06-4127; R10-6539; P05-02699; R06-4126] . However, 
change in pulmonary  function in the prior y ear does not predict the subsequent change in 
pulmonary  function in the following y ear [R14-1149 ]. In addition, none of these markers has 
been validated prospectively . Several serum proteins at baseline (e.g. KL -6, MMP -7, 
surfactant protein D) have also been shown to wea kly correlate with the clinical course of the 
disease [ R15-4126 ; R10-6378 ; R15-4125], but none of these markers have been assessed 
longitudinally .
A key  hallmark in the pathology  of IPF is dy sregulation in connective tissue turnover within 
the lungs, resulting in excessive accumulation of distorted extracellular matrix and scarring 
which is considered a final common pathway in lung fibrosis. This deranged equilibrium is 
determined b y several components including fibroblast proliferation, migratio n and 
differentiation, ECM s ynthesis by  active my ofibroblasts, collagen cross -linking and matrix 
degradation b y various enzy mes like metalloproteinases (MMPs). 
The prospective observational PROFILE study [R15 -1220] has recentl yshown that disease 
progression and prognosis can be determined through temporal changes in extracellular 
biomarkers indicating the defective and excessive matrix turnover potentially  directly  
reflecting disease activity. I n addition, the magnitude of chan ge in ECM biomarkers related 
to the subsequent risk of disease progression and these changes provided the ability  to predict 
outcome at an earlier stage (after 3 months) compared to ph ysiologic measures of lung 
function. I t remains to be determined whether baseline or change in ECM biomarkers will 
predict response to treatment.
Identify ing biomarkers to predict the clinical course and benefits of nintedanib therap y, e.g. 
effect of nintedanib on surrogate biomarkers earl y in the course of the disease remain s one of 
the most urgent and relevant challenges to improve overall patient management, prevent 
treatment delay  or overtreatment.
This study  is conducted to examine for the first time the treatment effect of nintedanib on 
change of biomarkers indicative of extracellular matrix turnover which have been shown 
recentl y to predict disease progression in the PROFILE stud y [R15 -1220] . 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 20of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015This study  further aims to confirm the association of biomarke r course during the first three 
months of treatment and disease progression as observed in PROFILE and to assess whether 
nintedanib treatment during the first 12 weeks alters this association or not .
TRIAL OBJECTIVES 2.2
The primary  objective of the trial will be t o assess the effect of nintedanib on rate of change 
in extracellular matrix (ECM) turnover biomarker CRPM over 12 weeks which has shown to
strongl y associate with disease progression in patients with I PF in the PROFILE cohort
[R15 -1220] .
A secondary  objective is to confirm the observed results from the PROF ILE cohort, i.e. to 
assess the predictive value of change in extracellular matrix (ECM) biomarker sCRPM , C1M 
and C3M over 12 weeks for disease progression as defined b y FVC decline ≥ 10% or death 
over 52 weeks [R15 -1220] .This wil l be done pr imarily  within patients randomised to 12 
weeks placebo treatment, since placebo treatment is expected not to impact change in 
extracellular matrix (ECM) biomarker sCRPM , C1M and C3M over 12 weeks nor disease 
progression which will facilitate in terpretation of obtained results. 
Additionally , a further secondary  objective will be to assess how nintedanib treatment during 
the first 12 weeks of the trial affects the association between change in extracellular matrix 
(ECM) biomarker sCRPM , C1M and C3M over 12 weeks and disease progression. The 
corresponding analyses will comprise all patients treated with nintedanib including patient s
who are initially  on placebo.
Analy ses related to both primary  and secondary  objectives need to be considered as a whole 
in order to understand the complex network of associations between biomarkers, their change 
over time, the potential impact of treatment and the ultimate outcome of disease progression.
Further objectives are to assess the effect of nintedanib on r ate of change in additional ECM 
turnover biomarkers and (based on the main and secondary objective) the predictive value of 
the corresponding rate of change for disease progression. Furthermore, the trial will evaluate 
changes in pulmonary  function over ti me using home and standard in clinic spirometry  and 
their correlation. 
BENEFIT - RISK ASSESSMENT 2.3
The favourable benefit -risk ratio based on the so far acquired knowledge about nintedanib is 
the rationale to conduct further studies with nintedanib in idiopat hic pulmonary  fibrosis.
As described in S ection 1 , patients with I PF, including patients with only  limited FVC 
impairment, may benefit from lesser decline in lung function and hence slower disease 
progression as a r esult of treatment with nintedanib [P15 -09946] . In addition, nintedanib 
significantl y reduced the risk of first acute exacerbation in 2 out of 3 clinical trials [P11 -
11216 , P14-07514].
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 21of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan2015Two thirds of the patients in this trial will be treated with placebo for the first 12 weeks of the 
trial. A 1:2 randomization (nintedanib:placebo) increases the number of patients treated with 
placebo during the first 12 weeks and consequ ently  increases the power of assessing the
association between change in the extracellular matrix (ECM) biomarker CRPM over 12 
weeks and disease progression in placebo treated patients.  Change in the extracellular matrix 
(ECM) biomarker CRPM over 12 weeks will be classified as stable or falling [ ≤ 0 
ng/ml/month] or rising [> 0 ng/ml/month
] in line with the PROFILE cohort [R15 -1220] .A 12 
week placebo period is considered acceptable given that the in -and exclusion criteria assure 
inclusion of patients with mostly  preserved lung function at baseline . In addition, it is unclear 
if patients would even receive antifibrotic treatment as in clinical practice . IPF patients with 
limited lung function impairment might not be reimbursed in some countries depending on a 
FVC % predicted threshold (e.g. >80%predicted).
Following the 12 week placebo controlled period all patients in this trial will continue further 
treatment with nintedanib. This will allow a ctive treatment also to patients previously  on 
placebo. In the subgroup of patients by  baseline FVC (>80% versus ≤ 80% predicted) in the 
pooled INPUL SIS data set, the risk of disease progression (time to FVC decline >10% or 
death) up to 12 weeks was low an d similar in patients treated with placebo and nintedanib 
(approximately  10% of patients, respectivel y), although there was a risk reduction in favour 
of nintedanib by  approx. 40% in the end of the 52 week treatment period for both subgroups 
and a consiste nt effect on reducing the annual rate of decline by  50%, similar to the primary  
outcome in the overall population [P15 -09946] .
The risks of treatment with nintedanib are described in Section 1.2 . The most common side 
effects of nintedanib are of gastrointestinal nature (diarrhea, nausea, vomiting, abdominal 
pain), as well as liver enzyme elevations.
Safety  monitoring in this trial will consist of regular visits to the investigational site, timel y 
blood analy ses and specific monitoring procedures to follow -up potential hepatic enz yme 
elevation (potential for drug -induced liver injury ), see also S ection 5.3.6.1.
In case of lack of tolerability , symptomatic treatment, dose adjustments and/or interruptions 
of trial drugs (at the discretion of the investigator) should be considered to allow for 
resolution of the sy mptoms ( Section 4.2.1).
Based on the mode of action of ninteda nib, especially  on the inhibition of VEGF or VEGF 
receptors, arterial h ypertension, gastrointestinal perforations, thromboembolism and bleeding 
have been identified as potential risks of nintedanib treatment. Therefore, patients requiring 
full dose concomi tant anticoagulation, fibrinoly sis or high- dose antiplatelet therapy  will be 
excluded from this trial.
The mode of action of nintedanib indicates a high potential for teratogenicity and/or 
embry otoxicity , including fetotoxicity /lethalit y. In women of childbearing potential receiving 
nintedanib, contraceptive measures must be employ ed 28 day s before treatment initiation, 
during the treatment and for a period of 3 months after last drug intake.
Overall, the clinical sa fety profile of nintedanib as establishe d during the development 
programs including patients with less advanced disease is interpreted as favourable for the 
intended indication of IPF .
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745-05 Trial Protocol Page 22of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40- 106- RD-03(12.0)/Saved on:30Jan20153. DESCRIPTION OF DESIG N AND TRIAL POPULATI ON
OVERALL TRIAL DESIGN AND PLAN 3.1
This is a multi -centre, multinational, prospective trial. The trial comprises two period s. The 
first period is a 12 week, randomi sed, double blind, placebo controlled, parallel group period 
to assess the effect of nintedanib 150 mg bid on change ofECM biomarker turnover 
indicative of disease progression compared to placebo. The second period is a single arm , 
open label, active treatment period ( nintedanib 150 mg bid) of 40 weeks duration. The total 
treatment period 
duration is 52 weeks. ( Table 3.1:1 ).
Table 3.1:1 Summary  of treatments
Number of patient s 
per treatment armTreatment period
Period 1
12 week, randomised, 
double blind, placebo 
controlled, parallel groupPeriod 2
40 week, single arm, 
open label, active 
treatment period
Treatment ~117 nintedanib 150 mg bid * nintedanib 150 mg bid *
Treatment ~233 placebo matching 
nintedanib 150 mg bid *nintedanib 150 mg bid *
Total number 
of patient s~350
*Permanent or intermittent dose reduction to a total daily dose of nintedanib 200 mg as well 
as subsequent re -escalation are allowed, further details are described in Section 4.2.1.
The overall trial scheme is presented in Figure 3.1:1.
Figure 3.1:1 Trial schemenintedanib 150 mg
bid / ~ 350 patientsScreening
(V1 -V2)
2 weeks(V10 -V11)
4 weeksTreatment Period/ 
Period 2 (V5-V10)
40 weeks ,
single arm, ope n label, 
active treatment
Follow-up nintedanib 150 mg bid / 
~117 patients
placebo 150 mg bid/
~233 patientsTreatment Period / Period 1
(V2-V5)12weeks , 
randomised, double blind, placebo 
controlled, parallel group
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 23of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015After signing the informed consent (prior to an y trial related procedures including an y 
medication washout), the HRCT scan and surgical lung biops y sample ( later if available) will 
be sent for central review. Screening visit (Visit 1) should only  be performed after the 
diagnosis of IPF has been con firmed b y the central review. The screening period, i.e. period 
between Visit 1 and 2 should last from 14 days(2 weeks) to a maximum of 28 day s (4 
weeks).
Patients whose central lab results are available andwho meet all inclusion and none of the 
exclusion criteria may be randomis ed into the 12 -week, double- blind treatment period in 
which they  will be receiving either of two possible treatments:  nintedanib of total daily  dose 
300 m g administered twice daily,150 mg in the morning and 150 mg in the evening or 
equivalent placebo bidin double -blind fash ion. The chance of receiving either of the above 
mentioned treatments wi ll be 1 (active treatment): 2 (placebo) .Randomi sation will be 
performed using an Interactive Response Technology  System (IRT). Following the 
randomi sed, double blind, placebo controlled treatment period ,all patients will enter the 
single arm, open label, active treatment period of 40 weeks . All patients previously  receiving 
placebo will start taking nintedanib . During the trial patients will be return ingto the clinic for 
the visits as per Flow Chart for the assessment of efficacy  and safet y parameters as well as
assessment of compliance with the study  drug. 
Dose adjustment visits may  occur at an y time to manage adverse events . Permanent or 
intermittent dose reduction to a total daily  dose of nintedanib 200 mg, i.e. 100 mg b id and 
drug interruptions are allowed to manage AEs as described in Section 4.2.1 . Re-escalation to 
nintedanib 150 mg bid is allowed as described in Section 4.2.1 .Each time a dose reduction or 
re-escalation is made, the patient must return for an unscheduled visit.
Upon completion of the 52 week treatment period (12 weeks Part 1 and 40 weeks Part 2) , 
patients will en ter a 28 day (4 week) Follow- Up perio d. Each p atient will attend a total of 12
scheduled visits (Visit 0 and Visits 1 to 11 scheduled as per Flow Chart ). Patients, who 
prematurel y and permanently  discon tinue study  treatment prior to 5 2 weeks, will be asked to 
return to the clinic and attend all visits as originally planned per protocol Flow Chart .
Each patient’s participation in the trial is estimated to last a total of approximately  58 weeks.
Depending on patient's informed consent, a blood sample fo r pharmacogenetics should be 
drawn at Visit 2 or at an y subsequent visit from any randomi sed patients who received at 
least one dose of trial medication.
For an overview plan of procedures please refer to the Flow Chart at the beginning of this 
protocol.
Adverse events will be collected, documented and reported from the time the patient signs an 
Informed Consent up until 28 day safter the last dose of study medication. 
3.1.1 Administrative structure of the trial
The sponsor of this trial is Boehringer Ingelheim (BI) .Clinical trial drug supplies , i.e. trial 
medication will be provided by the sponsor.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 24of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Boeh ringer Ingelheim has appointed the Trial Clinical Monitor, responsible for coordinating 
all required activities, in order to 
-manage the trial in accordance with applicable regulations and internal SOPs,
-direct the clinical trial team in the preparation, conduct, and reporting of the trial,
-ensure appropr iate training and information to L ocal Clinical M onitors (CML ), 
Clinical Research Associa tes (CRAs), and Investigators of participating countries.
Data Management and Statistical Evaluation will be done by  BI acc ording to BI SOPs.
Tasks and functions assigned in order to organise, manage, and evaluate the trial will be 
defined according to BI SOPs. A list of responsible persons and relevant local information 
can be found in the ISF.
A Coordinating Investigator h as been nominated and will be responsible to coordinate 
investigators at different centres participating in this multicentre trial. The Coordinating 
investigator was selected by  the sponsor.  will review the trial protocol, any subsequent 
amendments to t he protocol and the (draft) Clinical Trial Report (CTR). will provide  
signature on the final protocol signature page and amendments and will provide  signature 
on the CTR indicating that, to the best of the co-ordinator’s knowledge, the final CTR
accuratel y describes the conduct and results of the trial.
Sites selected for participation will consist of centres experi enced in the treatment and 
management of IPF.
The following local facilities/equipment along with the medicall y needed equipment to 
routinely  treat patients are required at the trial site: 
equipment for measuring body  height
scale s for measuring patient weight
sphygmomanometer (blood pressure instrument)
12-lead ECG device
refrigerator
freezer ( -20°C) 
laboratory  tabletop centrifuge (ambient)
equipment for DLCO measurements (or availability  to perform measurements if not 
available directly  at the site)
device for pulse oximetry  measurement
prem ises for performing PFTs, blood and/or urine sampling and handling of samples 
(PK/PD/PG/ biomarker and or safet y)
weather station (to measure atmospheric temperature, barometric pressure and 
humidity ), all parameters will be needed for spirometer calibrati on 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 25of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015internet access
analogue fax line
CROs: 
CRO for provision of in clinic spirometers and home spirometry  devices .
CRO/s for HRCT and surgical lung biops y reviews 
CRO for central laboratory  for safety laboratory , biomarkers, PK and 
pharmacogenetic sampling logistics . 
CROs for provision of CRAs. 
IRT: An IRT(IVRS/I WRS, ie I nteractive Voice/Web Response Sy stem) will be used for 
randomi sation in this trial and for appropriate re- supply  and assignments of trial medication 
to patients during treatment period. The ability  to unblind will be available via the I RT.
Relevant documentation on the participating (Principal) Investigators and other important 
participants will be filed in the trial master file (TMF) in accordance with BI SOPs
DISCUSSION OF TRIAL DESIGN, INCLUD ING THE CHOICE OF 3.2
CONTROL GROUP(S)
Patients with idiopat hic pulmonary fibrosis having a FVC of at least 80% of the predicted
normal value at baseline will be eligible for participation in this trial. I t is considered 
acceptable in this patient population to include a 12 week placebo -controlled treatment phase 
(refer to Section 2.3) inorder to compare the effect of nintedanib versus placebo on change in 
ECM biomarker turnover .
In the PROFILE stud y [R15 -1220] , these biomarkers have shown their predictive potential 
for disease progression as earl y as after the period of 3 months.
A 1:2 randomis ation (nintedanib:placebo) increases the number of patients treated with 
placebo during the first 12 weeks and consequently i ncreases the power of assessing the
association between change in the extracellular matrix (ECM) biomarker CRPM over 12 
weeks and disease progression in placebo treated patients.  Change in the extracellular matrix 
(ECM) biomarker CRPM over 12 weeks will b e classified as stable or falling [ ≤ 0 
ng/ml/month] or rising [> 0 ng/ml/month ] in line with the PROFILE cohort [ R15-1220 ].
Fibrotic remode lling of the lung interstiti al tissue with subsequent restrictive ventilatory  
defect re presents the core element of the histopathology  of IPF. Therefore, FVC decline is 
considered a marker of disease progression and will be assessed via supervised spirometry  at 
regular clinic visits as well as via home spirometry. Home spirometry  may  allow a more 
sensitive estimate of lung function decline based on more points of measurement resulting in 
higher accuracy  and/or less variability  in calculating the slope. Consequently , this study  will 
also provide the opportunity  to compare changes in FVC over t he course of the study  using 
standard clinic spirometry compared to home measurements, i.e. generate data on the general 
feasibility  and validity  of home spirometry  in IPF.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 26of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015After 12 weeks of double -blind treatment, all patients will enter the 40 week single active 
arm phase of the trial to potentially  benefi t from nintedanib treatment. T otal treatment 
duration of 52 weeks is considered adequate to assess disease progression and the predictive 
value of ECM biomarker turnover in this patient population.
Themost frequent s ymptoms in p atients with I PF aredyspnoea and cough. These s ymptoms 
substantially  reduce the quality  of life and c ause major restriction in every day life,as well as 
incapacit y in man y patients with I PF. Therefore, a number of patient- repor ted outcome 
instruments (questionnaires) will be used to document the effect of nintedanib on sy mptoms
(shortness of breath) and patient’s health related quality  of life.
The frequency  of visits will allow close monitoring of adverse events, as well as con trol of 
liver enzy me values ,consistent with the recommendations of the prescribing information for
nintedanib .
SELECTION OF TRIAL P OPULATION 3.3
Participation in this trial will be available to patients with I PF who meet the eligibility  
requirements specified in this protocol. 
Recruitment will be competitive. The patients w ill be recruited from approximately  100 trial
sites. Additional sites may  be initiated to ensure trial recruitment as well as sponsor timelines.
Every  effort should be made to keep patients in the study  until completion of all study  related 
procedures described in the clinical trial protocol. 
A log of all patients enrolled into the trial(i.e. who have signed informed consent) will be 
maintained in the I SF at the investigational site irrespective of whether they  have been treated 
with investigational drug or not.
3.3.1 Main diagnosis for trial entry
Any patients with confirmed diagnosis of IPF and who comply  with eligibility  requirements 
may qualify  for participation in the trial.
Please refer to Section 8.3.1 (Source Documents) for the documentation requirements 
pertaining to the in -and exclusion criteria.
3.3.2 Inclusion criteria
1.Written informed consent consistent with I CH-GCP and local laws, signed pri or to 
participation in the trial including any stud y related procedures being performed 
[including any required washout as well as sending HRCT and lung biopsies ( the 
latter if available )];  
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 27of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20152.Male or female patients aged ≥ 40 years at V isit 1;
3.A clinical diagnosis of IPF within the last 3years from Visit 0, based upon the 
ATS/ERS/JRS/A LAT 2011 guideline ( P11-07084 );
4. C hest high resolution computed tomograph y (HRCT) scan performed within 18
months of Visit 0;
5.Combination of HRCT pattern and surgical lung biopsy  pattern (the latter if 
available ) as assessed b y central review are consistent with the diagnosis of IPF
(Appendix 10.1 );
6.FVC ≥ 80% of predicted normal at visit 1. NOTE: If this is not achieved at the 
screening visit ,the visit may be repeated once within two weeks.
3.3.3 Exclusion criteria
1. ALT, AST > 1.5 fold upper l imit of normal (ULN) at V isit 11;
2. Total bili rubin > 1.5 fold ULN at V isit 11;
3. Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic 
impairment ;
4. Relevant airway s obstruction [ i.e.pre-bronchodi lator FEV1/FVC < 0.70      
(i.e. 70%) at Visit 1];
5. History  of m yocardial infarction within 6 months of visit 1 or uns table angina 
within 1 month of Visit 1 ;
6. Bleeding Risk:
• Known genetic predisposition to bleeding;
• Patients who require fibrinolysis, full -dose therapeutic anticoagulation 
(e.g. vitamin K antagonists, direct thrombin inhibitors , heparin, hirudin etc.) or 
high dose antiplatelet t herap y2;
• History  of haemorrhagic central nervous s ystem (CNS) e vent within 12 
months prior to V isit 1;
• History  of haemopt ysis or haematuria, active gastro -intestinal bleeding 
or ulcers and/or major injury  or surgery  within 3 months prior to Visit 1;
• International normalised ratio (INR) > 2 at V isit 11;
• Prothrombin time (PT) and partial thromboplastin time (PTT) > 150% 
of ULN at V isit 11;
7. Planned major3surgery  during the trial participation, including lung
transplantation, major abdominal or maj or intestinal surgery ;
8. History  of thrombotic event (including stroke and transient ischemic attack)
within 12 months of Visit 1;
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 28of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20159. Creatinine clearance < 30 mL /min calculated by  Cockcroft–Gault formula at
Visit 1 ( Appendix 10.2 );
10. Treatment with nintedanib, pirfenidone, azathioprine, cy clophosphamide,
cyclosporine, any  other investigational drug, n -acety lcysteine, 
prednisone/prednisolone >15 mg daily  or >30 mg every  2 day s OR use of 
other sy stemic corticosteroids as well as an y investigational drugs within 4 
weeks of Visit 2;
11. Known hy persensitivity  to nintedanib, peanut, soya or to any  other 
components of the study  medication;
12. Prior discontinuation of nintedanib treatment due to intolerability / adverse
events considered drug related;
13. A disease or condition which in the opinion of the investigator may  interfere
with testing procedures or put the patient at risk when participating in this trial;
14. Alcohol or drug abuse which in the opinion of the treating ph ysician would
interfere with the treatment and would affect patient’s ability  to participate in 
this trial;
15. Patients not able to understand and follow an y study  procedures such as but
not limited to home spirometry6, including completion of self-administered 
questionnaires without help;
16. Women who are pregnant, nursing, who plan to become pregnant while in the 
trial or female patients with positive pregnancy  (ß-HCG) test at Visit 1 and/or 
Visit 2;
17. Women of childbearing potential4not willing or able to use highl y effective
methods of birth control per ICH M3 (R2) that result in a low failure rate of 
less than 1% per year when used consistently  and correctly5.
NOTE: In women of childbearing potential receiving nintedanib, 
contracepti ve measures must be employed 28 days before treatment 
initiation, during the treatment and for a period of 3 months after last drug 
intake;
18. Patients with acute I PF exacerbation or any  respiratory  tract infection in the
four weeks prior to Visit 1 or d uring the screening period.
Visit 1 and/or Visit 2 should be postponed in case of an IPF exacerbation or 
respiratory  tract infection. Refer to Section 6.1 for information on re-
scheduling of visits;
19. Patients who are or h ave been participating in another trial with investigational
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 29of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015drug/s within one month prior to Visit 1 and patients who have previousl y 
been enrolled in this trial.
1Laboratory parameters found abnormal at visit 1 may be re -tested once prior to      
Visit 2.
2Exceptions: prophy lactic low dose heparin or heparin flush as needed for 
maintenance of an indwelling intravenous device (e.g., enoxaparin 4000 IU s.c. per 
day) and prophy lactic use of antiplatelet therapy  (e.g., acety l salicy lic acid up to 325 
mg/d, and/ or clopidogrel at 75 mg/d, and/ or equivalent doses of other antiplatelet 
therap y).
3Definition of major is per investigator judgement.
4Women of childbearing potential are defined as: Any  female who has experienced 
menarche and does not meet the cri teria for "women not of childbearing potential” 
defined as: Women who are postmenopausal (12 months with no menses without an 
alternative medical cause) or who are permanentl y sterili sed (e.g., tubal occlusion, 
hysterectom y, bilateral oophorectom y or bilat eral salpingectomy ). 
5A list of contraception methods meeting these criteria is provided in the patient 
information .
6Patient will need to perform at least one home spirometry manoeuv rebetween Visit 1 
and Visit 2 (in order to obtain baseline PFT values ) to be eligible for the trial.
3.3.4 Removal of patients from therapy or assessments
Remo val of individual patients 3.3.4.1
An individual patient is to be withdrawn from trial treatment if:
•The patient withdraws consent for study  treatment or study  participation, without t he 
need to justify  the decision;
•The patient needs to take concomitant drugs that interfere with the investigational 
product (Section 4.2.2 );
•The patient can no longer be trea ted with trial medication for other medical reasons 
(such as surgery , adverse events, other diseases, or pregnancy );
If a patient becomes pregnant or pregnancy  is suspected during the trial, the patient 
will be permanentl y discontinued from the study treat ment and will be followed up 
until birth or otherwise termination of pregnancy , please see Section 5.3.7 .
•The patient experiences signs and s ymptoms of acute myocardial isch emia or stroke;
•The patient experiences hepatic injury  defined as follows:
-ALT and/or AST ≥8 fold ULN
-ALT and/or AST ≥ 3 fold ULN and total bilirubin >2 fold ULN
-ALT and/or AST ≥ 3 fold ULN and unexplained INR > 1.5
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 30of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015-ALT and/or AST ≥ 3 fold ULN and unexplained eosinophilia (> 5%)
-ALT and/or AST ≥ 3 fold ULN and appearance of fatigue, nausea, vomiting, 
right upper abdominal quadrant pain and tenderness, fever and/or rash.
•For potential drug induced liver injury  (DILI) follow up requirements please see 
Section s 4.2.1.3 and5.3.6.1 .
•The patient experiences unacceptable toxicity despite dose adjustments and 
supportive care
•Gastrointestinal perforation;
•Major surgery  including abdominal or intestinal surgery ;
•Signs or s ymptoms of acute my ocardial ischemia, stroke, deep vein thrombosis and 
pulmonary  embolism
In addition, permanent discontinuation of nintedanib should be considered in the following 
situations:
•Patients who require full dose therapeutic anticoagulation or high dose a ntiplatelet 
therap y;
•Increased risk of bleeding (e.g. gross/ frank haemopty sis or haematuria, active 
gastro -intestinal bleeding or ulcers).
In such cases, continuation of nintedanib should be discussed with the patient and the 
decision based on an individ ual benefit -risk assessment documented in the source data. 
If a patient permanentl y discontinues a study  drug, he/she will undergo procedures for earl y 
treatment discontinuation and will be invited to attend all planned study  visits until week 56 
as outlined in the flow chart .
For all patients the reason for withdrawal (e.g. adverse events) must be recorded in the 
(e)CRF. These data will be included in the tri al database and reported.
Discontinuation of the trial by  the sponsor 3.3.4.2
Boehringer Ingelheim reserves the right to discontinue the trial overall or at a particular trial 
site at any  time for the following reasons:
1.Failure to meet expected enrolment goals overall or at a particular trial site
2.Emergence of an y efficacy /safet y information invalidating the earlier positive benefit -
risk-assessment that could significantl y affect the continuation of the trial
3. Violation of good clinical p ractice ( GCP ), the clinical trial protocol ( CTP), or the contract 
disturbing the appropriate conduct of the trial
The Investigator / the trial site will be reimbursed for reasonable expenses incurred in case of 
trial termination (except in case of the thi rd reason).
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 31of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20154. TREATMENTS
TREATMENTS TO BE ADM INISTERED 4.1
Patients will be randomi sed 1: 2to 300 mg nintedanib daily  (i.e.one capsule of nintedanib 
150 mg in the morning and one capsule of nintedanib 150 mg in the evening )or matching 
placebo (i.e. one capsule of matching placebo in the morning and one in the evening )during 
the first 12 weeks of the treatment period . For the subsequent 40 weeks all randomis ed 
patients will enter the single active arm treatment . All patients previously  receiving placebo 
will start taking nintedanib.
During the trial, permanent or intermittent dose reduction to a total daily  dose of nintedanib 
200 mg, i .e.100 mg bid and intermitte nt drug interruptions are allowed to manage AEs as 
described in Section 4.2.1 . Re-escalation to nintedanib 150 mg bid is also allowed as 
described in Section 4.2.1.
Trial medication will be provided as a medication kit. One medication kit will contain seven 
blister card s each containing 10 soft gelatin capsules of either blinded nintedanib 150 mg, or 
blinded nintedanib 100 mg, or matching placebo (for blinded part of the trial) and open label 
nintedanib 150 mg, or open label nintedanib 100 mg (for the open label part) thus allowing 
sufficient amount of medication for approximately one month.  Sufficient amount of kits, 
each identified with a unique medication number, will be dispensed to each patient 
throughout the trial via IRT. No active comparator is us ed in this trial.
Trial medication is manufactured by  Boehringer Ingelheim .
4.1.1 Identity of BI investigational product (s)and comparator product(s)
Table 4.1.1: 1 Nintedanib:
Substance: Nintedanib (Ofev®)
Pharmaceutical formulation: Soft gelatin capsule
Source: BI Pharma GmbH & Co. KG
Unit strength: 150 mg, 100mg
Posology 1 capsule, bid
Route of administration: Oral (swallowed)
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 32of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Table 4.1.1: 2 Placebo matching Nintedanib
Substance: N/A
Pharmaceutical formulation: Soft gelatin capsule
Source: BI Pharma GmbH & Co. KG
Unit strength: N/A
Posology 1 capsule, bid 
Route of administration: Oral (swallowed)
4.1.2 Method of assigning patients to treatment groups
To guarantee the double- blind design of the stud y, all treatments will be indistinguishable for 
the patient as well as for the investigator.
After final assessment of all inclusion and exclusion criteria, each eligi ble patient will be 
randomly  assigned in 1:2 ratio (treatment: placebo) to one of the two treatment options at 
Visit 2 (double blind phase applicable to the first 12 weeks onl y). An interactive voice 
response s ystem (IRT) will be used for randomis ation to a specific treatment group in this 
trial and for the appropriate supply  and re -supply  of study  medication to patients throughout 
the trial. Patients will be randomis ed to receive either an active drug at a dosage of 150 mg 
bid or matching placebo. 
Documents such as but not limited to user guides, instructions, worksheets on the IRT will be 
stored in the I SF.
Note that the medication number is different from the patient number (the latter one is 
assigned after the informed consent process has been co mpleted). 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 33of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20154.1.3 Selection of doses in the trial
A dose of nintedanib 150 mg bid (total dail y dose of 300 mg) was selected for this trial as this 
is the recommended dose based on prescribing information in partic ipating countries as well 
as the dose that has shown to be efficacious i n two replicate phase III trials. 
Dose adjustments arepermitted as per Section 4.2 .
4.1.4 Drug assignment and administration of doses for each patient
Drug assignment
Dosage for an individual patient will be as signed by  means of an I RT at Visit 2. Patient s
will be randomis ed to receive either an active drug at a dosage of 150 mg bid or matching 
placebo.
At V isit 5, all patients will start receiving open label nintedanib for the remainder of the trial.  
Patients previously  receiving placebo will now start receiving nintedanib. All p atients will 
remain on the same dose they  were previousl y receiving unless prescribed o therwise b y the 
investigator. Patients, site staff and trial team will remain blinded to patient ’s previously  
randomi sed treatment group.
Study  treatment will comprise of 1 capsule twice daily  throughout the trial(refer to Section 
4.1). Treatment kits containing 4 weeks + 1 week reserve treatment (one treatment kit 
containing 7 blister cards each having 10 capsules) will be dispensed to the patient s.  
To ensure patients receive adequate supply  of study  medication, kits will be dispensed at 
clinic visits in quantities outlined in Table 4.1. 4: 1. Unscheduled re -supplies with additional 
medication kits will be possible via the I RT.
Table 4.1.4: 1 Quantity  of medication kits dispensed
Visit Week Number of medication 
kits
2 0 1*
3 4 1*
4 8 1*
5 12 3**
8 24 3**
9 36 4**
* Double- blind study  drug
**Open label active treatment study  drug
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 34of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015The investigational product should only  be dispensed to participating patients accor ding to 
the protocol by  authoris ed personnel as documented on the Investigator’s Trial Staff List . All 
unused medication must be returned to the Sponsor. Receipt, usage and return must be 
documented on the respective forms. An y discrepancies must be accounted for.
Drug administration
•Study  drug will be administered orall y on a twice daily  basis (bid). At all clinic visits 
thestudy drug will be administered at the study site (after any sampling 
procedures and PFTs) .The patients should swallow the study  medication unchewed 
together wit h a glass of water (~250 mL), and should observe a dose interval of 
approximately 12 hours. Study  drug needs to be taken at approximately  the same time 
every  day (preferabl y between 06:00 and 11:00 in the morning, and between 18:00 
and 23:00 in the evening ). 
•Because nintedanib may cause stomach discomfort, it is recommended to take the 
administered drug after the meal . 
•If a dose of nintedanib is missed , i.e. not taken between 06:00 and 11:00 in the 
morning, and between 18:00 and 23:00 in the evening, administration should resume 
at the next scheduled time at the recommended dose. No catch up of missed doses is 
permitted.
Patients experiencing adverse effects requiring temporary  drug discontinuation (refer to 
Section 4.2.1 and 4.2.2 ) may  start to receive study  drug at 100 mg bid. The dose can also be 
reduced without pri or discontinuation, i.e. immediately  stepping down from 150 mg bid to 
100 mg bid if necessary . In the case of severe to xicity  or when the reduced dose is again not 
tolerated, drug treatment must be sto pped and cannot be restarted. All dose reductions must 
be approved b y the Investigator or delegated site staff at the site (during the scheduled or 
unscheduled visit) and the reason for reduction must be documented.  
In case of adverse events requiring dose reduction (refer to Sections 4.2.1 and 4.2.2 ), 100 mg 
bid (or matching placebo) will be assigned by  IRT upon call of the Investigator. The colo ur 
of the 150 mg capsules and the 100 mg capsules w ill be slightly different; the packaging will 
remain the same (same number of capsules per blister, sam e numb er of blisters per box ).  
If the reduced dose is well t olerated, re -escalation to 150 mg bid is possible, according to 
procedures described in Section 4.2.1.1 . 
The amount of study  drug dispensed at the time of dose reduction and dose re -escalation is 
dependent upon the amou nt of time between the unscheduled visit and the next planned study  
visit.  Therefore at unscheduled visits for dose reductions and dose re -escalations, I RT will 
assign onl y the number of boxes of study medication needed until the next predicted planned 
patient visit as noted within the I RT s ystem.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 35of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20154.1.5 Blinding and procedures for unblinding
Blinding 4.1.5.1
Patients, Investigator s and every one involved in trial conduct or analy sisor with an y other
interest in this double -blind trialwill remain blinded with regard to the randomi sedtreatment 
assignments until after database lock.
The randomis ation code will be kept secret by  Clinical Tri al Support up to database lock.
Unblinding and breaking the code 4.1.5.2
Emergency  unblinding will be available to the Investigator / Pharmacist / investigational drug 
storage manager via IRT. It must only  be used inan emergency  situation when the identity  of 
the trial drug must be known to the Investigator in order to provide appropriate medical 
treatment or otherwise assure safety  of trial participants . The reason for unblinding must be 
documented in the source d ocuments and/ or appropriate CRF page along with the date and 
the initials of the person who broke the code.
Due to the requirements to report Suspected Unexpected Serious Adverse Reactions
(SUSARs), it may  be necessary  for a representative from Boehringer Ingelheim’s
Pharmacovigilance group to access the randomisation code for individual patients during trial
conduct. The access to the code will onl y be given to authorised Pharmacovigilance
representatives and not be shared further.
4.1.6 Packaging, labelling , and re -supply
For de tails of packaging and the description of the label, refer to the ISF.
4.1.7 Storage conditions
Drug supplies will be kept in their original packaging and in a secure limited access storage 
area according to the recommended storage conditions on the medication label. A 
temperature log must be maintained for documentation.
If the storage conditions are found to be outside the specified range, the local clinical monitor 
(as provided in the list of contacts) must be contacted immediately .
All used and unused trial medication must be returned to the sponsor. Receipt, usage and 
return must be documented on the respective forms. Account must be given for an y 
discrepancies.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 36of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20154.1.8 Drug accountability
The Investigator and/or Pharmacist and /or investigational drug storage mana ger will receive 
the investigational drugs delivered b y the Sponsor when the following requirements are 
fulfilled:
Approval of the trial protocol by  the IRB / ethics committee, 
Availability  of a signed and dated clinical trial contract between the Sponsor and the h ead 
of the investigational site,
Approval/notification of the regulatory  authority , e.g. competent authorit y,
Availability  of the curriculum vitae of the principal Investigator ,
Availability  of a signed and dated clinical trial protocol
Availability  of the proof of a medical license for the principal Investigator
Availability  of Form 1572 (as applicable)
The Investigator and/or Pharmacist and/or investigational drug storage manager must 
maintain records of the pro duct’s delivery  to the trial site, the inventory  at the site, the use by  
each patient, and the return to the Sponsor or alternative dispos al of unused products. 
These records will include dates, quantities, batch /serial numbers, expiry  (‘use -by’) date s, 
and the unique code numbers assigned to the investigational product and trial patients. The 
Investigator / Pharmacist / investigational drug storage manager will maintain records that 
document adequately that the patients were provided the doses specifi ed by the CTP and 
reconcile all investigational products received from the Sponsor . At the time of return to the 
Sponsor and/or appointed CRO, the Investigator / Pharmacist / investigational drug storage 
manager must verify  that all unused or partiall y use d drug supplies have been returned by  the 
clinical trial patient and that no remaining supplies are in the Investigator ’s possession.
CONCOMITANT THERAPY, RESTRICTIONS, AND RE SCUE 4.2
TREATMENT
4.2.1 Rescue medication, emergency procedures, and additional treatment(s)
Rescue medication to reverse the action of nintedanib isnot available .
Recommendations for managing adverse events (exceptions include diarrhea 4.2.1.1
and liver enzyme elevations )
•If a patient experiences adverse events considered related to the trial medication ,
symptomatic treatment should be initiated (e.g. anti -emetic treatment such as 
dimenhy drinat if appropriate). 
•Patients experiencing adverse events considered related to nintedanib may  require 
drug interruption or reduction of dose (at the discretion of the investigator) to allow 
for resolution of s ymptoms. 
•After resolution of AE, nintedanib may be reintroduced and re -escalated to the higher 
dose (at the discretion of the investigator):
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 37of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015-If dose has been reduced, consider re -escalation to 150 mg bid  
-If treatment was temporarily  interrupted, resume treatment at the full dose 
(150 mg bid), or at the reduced dose (100 mg bid), which subsequentl y ma y be 
re-escalated to the full dose (150 mg bid).
•For adverse events not related to the trial medications , treatment interruption s are 
allowed. Nintedanib should then be re sumed at the same dose taken prior to 
interruption.  
•In the occurrence of acute IPF exacerbations all treatment options considered 
adequate b y the investigator are allowed , except concomitant treatment with 
pirfenidone .  
Recommendations for m anagement of diarrhea 4.2.1.2
The Common Terminology  Criteria for Adverse Eve nts (CTCAE Version 4.0) grading will 
be used to grade the severity  of all AEs and SAEs of diarrhea. Management 
recommendations for diarrhea are based on the CTCAE grades .
In general, diarrhea should be managed as earl y as possible after onset of first sy mptoms with 
standard antidiarrheal s ymptomatic treatment, e.g. lop eramide.
The medical judgement should be used in decision of the use preventive treatment with 
loperamide after the first episode of diarrhea .  
If diarrhea persists despite optimal sy mptomati c treatment, treatment interruption (for a 
maximum of 4 weeks) and dose reduction of nintedanib should be considered based on the 
recommendations described in Table 4.2.1.2: 1
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 38of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Table 4.2 .1.2: 1 Recommendations for m anagement of diarrh ea
CTCAE 
GradeDescription Symptomatic Treatment Action with study medication
1Increase of <4 
stools per day over 
baselineInitiate anti -diarrheal medicines at 
first signs of symptoms (e.g., 4 
mg loperamide followed by 2 mg 
after each loose stool or every 2 -4 
hours to a maximum of 16 
mg/day1) until bowel movements 
cease for 12 hoursContinue same dose of study 
medication
2Increase of 4 -6 
stools per day over 
baselineInitiate/continue anti -diarrheal 
medicines;
If diarrhea grade 2 persists for 
≥48-72 hours assess for 
dehydration and electrolyte 
imbalance; 
In addition, consider IV fluids and 
electrolyte replacement as 
clinically indicated.If diarrhea grade 2 persists for ≥48-
72 hours despite optimal 
symptomatic care: 
1. Interrupt study medication 
until recovery
2. Reduce dose to 100 mg bid 
after recovery 
3. Re-escalate to 150 mg bid if 
deemed clinically 
appropriate
3
Or
4Increase of ≥ 7 
stools per day over 
baseline; 
incontinence; 
Or
Life threatening 
consequencesFollow recommendations above.
In addition, consider stool work -
up to exclude infectious colitis; 
aggressive IV fluid replacement 
≥24 hours, hospitalisation as 
clinically indicated; consider 
referral to a GI specialist to rule 
out potential di fferential 
diagnoses.1. Interrupt study medication
until recovery
2. Reduce dose to 100 mg bid 
after recovery
3. Consider re -escalation to 
150 mg bid if deemed 
clinically appropriate
In case of recurrence of diarrhea
grades 3 or 4 despite optimal 
symptomatic treatment and dose 
reduction, study medication should 
be permanently discontinued.
1Refer to national prescribing information
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 39of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Recommendations for management of liver enz yme elevation 4.2.1.3
For a detailed guidance on how to manage liver enzy me elevations, please refer to table 
4.2.1.3: 1
Table 4.2.1. 3: 1 Recommendations for managing liver enz yme elevations
AST /ALT ≥3 but <5 x ULN AST /ALT ≥5 but <8 x ULNSigns of hepatic 
injury 2
Reduce study medication to 100 mg bid or 
interrupt (at the discretion of the 
investigator) 
Repeat Lab tests1in 48/72 hours, at week 1 
and week 2 Interrupt study medication
Repeat Lab tests1in48/72 hours, at w eek1
and week 2 Perm anently 
discontinue study 
medication
If AST /ALT < 3 x 
ULN within 2 weeksIf AST /ALT 
≥3 ULN
at2 weeksIf AST /ALT < 3 x 
ULN within 2 weeksIf AST /ALT ≥3 
ULN
at2 weeks
Re-escalate study 
medication to 150 mg 
bid if reduced ; restart at 
100 mg bid if 
interrupted
Repeat Lab tests1in 2 
and 4 w eeksInterrupt study 
medication
Repeat Lab 
tests1in 1 and 2 
weeksReintroduce study 
medication at 100 mg 
bid
Lab tests1in 1, 2 and
4weeksPermanently 
discontinue study 
medication
If AST / ALT ≥ 3 x 
ULN within 2 weeksIf at 2 weeksIf AST / ALT ≥ 3 x 
ULN within 2 weeks
Permanently 
discontinue study 
medication AST / ALT      
< 3 x ULN
reintroduce 
study 
medication; lab 
tests1every 
week as needed
If AST / ALT ≥ 
3 x ULN
permanently 
discontinue 
study 
medication Permanently 
discontinue study 
medication
1Laboratory  tests include AL T, AST, total bilirubin, eosinophils, I NR
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 40of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20152Signs of hepatic injury  are defined as:
ALT and/or AST ≥8 fold ULN
ALT and/or AST ≥3 fold ULN and total bilirubin ≥2 fold ULN
ALT and/or AST ≥3 fold ULN and unexplained INR > 1.5
ALT and/or AST ≥3 fold ULN and unexplained eosinophilia (> 5%)
ALT and/or AST ≥ 3 fold ULN and appearance of fatigue, nausea, vomiting, right 
upper abdominal quadrant pain or tenderness, fever and/or rash.
For potential drug induced liver injury  (DILI) follow up requirements please see Section 
5.3.6.1 .
Immediately refer to Section 5.3.6.1 in case AST and/or ALT ≥3 fold ULN is combined wi th 
total bilirubin ≥2 fold ULN.
Management of acute IPF exacerbations and acute deteriorations 4.2.1.4
In case of acute IPF exacerbation, all treatment options considered adequate by  the 
Investigator / caregiver are allowed , except concomitant treatment with pirfenidone.   
Although it is not generally recommended, the patient may  interrupt study  treatment if this is 
considered necessary  (e.g., if short -term full anticoagulation is performed). In case of 
significant deter ioration ( absolute FVC decline >10 %, DL CO >15%) all approved 
medications can be freely  initiated or increased at the investigator‘s discretion.
Definition of Acute IPF Exacer bations
Otherwise unexplained clinical features within one month, including all of the following:
• Unexplained worsening or development of d yspnoea within 30 day s;
• New diffuse pulmonary infiltrates on chest X -ray, and/or new HRCT parenchy mal 
abnormalit ies with no pneumothorax or pleural effusion (new ground -glass opacities) 
since last visit;
• Exclusion of infection as per routine clinical practice and microbiological studies;
• Exclusion of alternative causes as per routine clinical practice, including :
oLeft heart failure
oPulmonary  embolism
oIdentifiable cause of acute lung injury
4.2.2 Restrictions
Restrictions regarding concomitant treatment 4.2.2.1
Concomitant medications (or therap y) to provide adequate care may  be given as clinicall y 
necessary . If restricted concomitant therap y is necessary treatment with study medication 
should be permanentl y discontinued (except in case of acute IPF exacerbations –refer to 
Section 4.2.1.1 ).
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 41of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Table 4.2.2.1: 1 Permitted and Restricted Concomitant therapy  
Prior to 
randomi sationDuring 
treatment 
periodAfter EOT 
(Follow -up 
Period)After early
EOT5
NintedanibNot permitted in 
the 4 weeks prior 
to visit 2 1Study 
medicationPermitted Permited6
Pirfenidone , N-
acetylcysteine, 
Azathioprine, 
Cyclophosphamide,  
CyclosporineNot permitted in 
the 4 weeks prior 
to visit 2 1Not permitted Not permitted Permitted
Prednisone / 
Prednisolone and/or 
other systemic
corticosteroid2Not permitted in 
the 4 weeks prior 
to visit 2 1Not permitted Not permitted Permitted
Investigational 
MedicationNot permitted in 
the 4 weeks prior 
to visit 2 1Not permitted Not permitted Not permitted
Anticoagulation at full 
dose3,antiplatelet 
therapy at high dose 4,
fibrinolysisPermitted Not permitted Not permitted Permitted
1. Washout should not occur before the patient has signed informed consent
2. Prednisone / Prednisolone >15mg daily  or >30 mg ev ery 2 da ys OR use of other systemic 
corticoster oids within 4 weeks of visit 2.
3.Anticoagulation at full dose (vitamin K antagonists, direct thrombin inhibitors , heparin, 
hirudin, etc). Exceptions: prophy lactic low dose heparin or heparin flush as needed for 
maintenance of an indwelli ng intravenous device (e.g. enoxaparin 4000 I.U s.c per day)
4.Antiplatelet therap y at high dose. Exceptions: prophy lactic use of antiplatelet therap y 
(e.g. acet ylsalicy lic acid up to 325 mg/day  and/or clopidrogrel at 75 mg/day  and/or 
equivalent doses of oth er antiplatelet therapy ) is allowed 
5.For patients who withdrew study  medication before the planned EOT date and decide to 
attend all remaining study planned visits.
6.At the discretion of the treating ph ysician.
Restrictions on diet and life sty le 4.2.2.2
There are no restrictions on diet and life sty le.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 42of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Restrictions regarding women of childbearing potential 4.2.2.3
The anti -angiogenic properties of nintedanib indicate a high potential for teratogenicit y 
and/or embry otoxicity , including fetoto xicity /lethality . In women of childbearing potential 
receiving nintedanib, contraceptive measures must be employ ed 28 day s before treatment 
initiation, during the trial and for a period of 3 months after last drug intake.
TREATMENT COMPLIANCE 4.3
The Investigator will maintain accurate records of receipt of all study  medication, including 
dates of re ceipt. In addition, accurate records will be kept regarding when and how much of 
each stud y medication is dispensed to, and used by each individual patient in the study . 
Reasons for deviating from the expected dispensing regimen must be recorded. A Drug 
Accountability  Form, provided for this purpose, will be signed by  the Investigator or delegate 
at the conclusion of the study . At the completion of the study , in order to satisfy  regulatory  
requirements regarding drug accountability  and destruction, all used and unused packages 
must be returned to the Sponsor or its designee. 
Patients are requested to bring all remaining trial medication including empty  package 
material with them when attending visits.
Based on capsule counts, treatment compliance will be c alculated as the number of capsules 
taken, divided by the number of capsules which should have been taken according to the 
scheduled period, multiplied by  100. A compliance worksheet will be provided in the I SF. 
Treatment compliance (%) =Number of capsules actually  taken 100
     Number of capsules which should have been 
taken
If the number of doses taken is not between 80 -120% without identified cause like AE or 
consent withdrawal, site staff will explain to the patient the importance of treatment 
compliance. 
Compliance will be verified by  the on -site monitor authoris ed by the Sponsor.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 43of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20155. VARIABLES AND THEIR ASSESSMENT 
TRIAL ENDPOINTS 5.1
Note that all endpoints based on spirometry  are measured b y clinic spirometry  unless 
explicitly  stated otherwise.
5.1.1 Primary Endpoint
The primary  endpoint is the rate of change (slope) in blood CRPM from baseline to week 12 .
5.1.2 Secondary Endpoints
The key secondary  endpoint is the proportion of patients with disease progression as defined 
by absolute FVC (% predicted) decline ≥10% or death until week 52 based on in clinic 
supervised spirometry .
Secondary  endpoints are the rate of change (slope) in blood C1M from baseline to week 12 
and the rate of change (slope) in blood C3M from baseline to week 12.

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 44of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015ASSESSMENT OF EFFICA CY 5.2
Measurements of biomarkers
Bloo d samples collected from patients at visits will allow measurement of following 
concentrations:  collagen 1 degraded by  MMP -
2/9/13 (C1M), collagen 3 degraded b y MMP -9(C3M),
 C-reactive protein degraded b y MMP -1/8 (CRPM), and citrullinated vimentin
Sample collection is described in Section 5.5 . More details of sample collection and 
processing will be given in a lab manual.
Measurements of in clinic FVC
Spirometry  devices for in clinic measurements as well as devices f or home spirometry will be 
supplied by  a central ven dor to all participating sites.
In clinic s pirometry  performance will be centrall y reviewed . On- going feedback and training 
will be provided. Predicted normal values shall be calculated according to ECSC [R94 -1408] .
The spirometers and their use, including daily  calibration, must meet ATS/ ERS criteria (P05-
12782 ). Spirometry  will be conducted while the patient is in a seated position. The test will 
be done in triplicate and selection of the best result done according to the guidelines. 
Spirometric results will be electronicall y transmitted and confirmed b y centra l reading.
Further details on in clinic spirometry  shall be provided in the I SF.
For each patient, pulmonary function testing will alway s start at approximately  the same time 
of the day within ± 90 minutes maximum difference from measurement time at Visit 1. 
On day s of clinic visits (including the screening visit), patients must refrain from strenuous 
activity  at least 12 hours prior to pulmonary  function testing.

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 45of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Smoking should be discouraged throughout the study  day (clinic visit) and will not be 
permitted in the 30- minute period prior to spirometry . Patients should also avoid cold 
temperatures, environmental smoke, dust, or areas with strong odo urs (e.g. perfumes).
Washout of bronchodilators (betamimetics and anticholinergics) need to be observed prior to 
in clinic spirometry  (8 hours for short acting and 24 hours for long acting bronchodilators). 
 
 
 
 
 
 
 
 
 
Carbon Monoxide Diffusion Capacity and Oxygen Saturation.
The site will use its own carbon monoxide diffusion capacity  (DL CO) equipment and 
conduct all measurements with the same equipment (e.g. if several devices would be 
available at the site). Single -breath DL CO will be carried out according to the ATS / ERS 
guideline on DLCO measurements [ R06-2002 ]. Before beginning the test, the man oeuvers 
should b e demonstrated and the subject carefull y instructed. Please refer to Appendix 10. 5for 
additional information. The DL CO assessment should be per formed after the FVC 
assessment.
Oxygen saturation (Sp O2) will be measured at rest by  standard pulse oximetry  (unaffected 
skin of earlobe or fingertip or forehead) and the recorded value will be entered in eCRF.
 
ASSESSMENT OF SAFETY 5.3
5.3.1 Physical examination
Physical examination includes assessment of heart, lung, abdomen and measurement of 
weight. H eight will also be measured at V isit 1. Abnormal finding at the time of screening 
will be recorded as baseline conditions on the appropriate eCRF page. New abnormal 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 46of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015findings or worsening of baseline conditions detected at the subsequent ph ysical 
examinations will be recorded as adverse events on the appropriate eCRF page.
5.3.2 Vital Signs
Vital signs including measurements of s ystolic and diastolic blood pressure and pulse rate, 
will be measured with the patient seated after having rested for at least 5 minutes at each on 
site visit .
5.3.3 S afety laboratory parameters
The laboratory  tests will include:
•Haematology : complete blood count with platelet count and automated differential.
•Chemistry : sodium, potassium, creatinine, creatinine clearance calculated by  
Cockcroft –Gault formula, aspartate aminotransferase (AST), alanine transaminase 
(ALT), gamma -glutamy l transferase  (GGT), total protein, alkaline phosphatase 
(ALP), total bilirubin, lactate dehy drogenase (LDH), creatinine kinase an d thy roid 
stimulating hormone (TSH).
•Coagulation: International normalized ratio (INR) and partial thromboplastin time 
(PTT).
•Urine: pregnancy  testing 
If laboratory  values indicate toxicity , adequate and more frequent blood sampling will be 
performed at the discretion of the investigator.
Laboratory  anal ysis during main visits will be done using central laboratory  services. Venous 
whole blood will be collected in appropriate s yringes provided b y the sponsor through the 
assigned central laboratory . Nofasting is required. Details regarding centrifuge, processing, 
storage and shipment of samples will be determined by  the central laboratory  in accordance 
with the sponsor. The investigators will be informed and instructed b y the central laboratory 
and det ailed documentation will be included in the I SF.
In case of liver enz ymes elevation, close monitoring must be ensured b y the investigator 
(Section 4.2.1.3 ).
5.3.4 Electrocardiogram
12-lead ECGs are to be conducted with site equipment as specified in the Flow Chart . 
Changes should be examined, compared to previous test, and assessed for clinical relevance. 
Clinically  relevant fi ndings at Visit 1 will be recorded as baseline conditions, new abnormal 
findings thereafter will be recorded as adverse events.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 47of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20155.3.5 O ther safety parameters
Medical history
All active and relevant historical disorders will be recorded on the Medical History /Baseline 
Conditions eCRF page at the screening visit (Visit 1).
A patient diary willbe use d by all patients in this trial. The diary  will be used to prompt 
patient recollection during adverse event , concomitant therapies and times of drug intake 
three day s prior to the PK sampling. Instructions for use of the diary  will be provided in th e 
ISF.
5.3.6 Assessment of adverse events
Definitions of AEs 5.3.6.1
Adverse event
An adverse event (AE) is defined as a ny untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal product and which does not necessarily  have 
to have a causal re lationship with this treatment.
An AE can therefore be any  unfavourable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
product, whether or not considered related to the medicinal product.
Adverse reaction
An adverse reaction is defined as a response to a medicinal product which is noxious and
unintended. Response in this context means that a causal relationship between a medicinal
product and an adverse event is at least a reasonable possibility . Adverse reactions may  arise
from use of the product within or outside the terms of the marketing authorisation or from
occupational exposure. Conditions of use outside the marketing authorization include off -
label use, overdose, misuse, abuse and medication errors.
Serious adverse event
A serious adverse event (SAE) is defined as any  AE which:
results in death,
is life -threatening,
requires inpatient hospitalisation or prolongation of existing hospitalis ation,
results in persistent or signif icant disability  or incapacity ,
is a congenital anomal y/birth defect,
or
is to be deemed serious for an y other reason if it is an important medical event when 
based upon appropriate medical judgment which may  jeopardize the patient and may  
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 48of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015require medical or surgical intervention to prevent one of the o ther outcomes listed in 
the above definitions. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalisation or development of dependency  or 
abuse. An y suspected transmission via a medicinal product of an infectious agent is 
considered a serious adverse reaction.
Life-threatening in this context refers to an event in which the patient was at risk of death at 
the time of the event; it does not refer to an event that hy pothetically  might ha ve caused death 
if more severe.
For Japan only : The following events will be handled as “deemed serious for any  other 
reason”. An AE which possibly  leads to disability will be reported as an SAE.
AEs considered “Always Serious”
Cancers of new histology and exacerbations of existing cancer must be reported as a serious 
event regardless of the duration between discontinuation of the drug and the occurrence of the 
cancer.
In accor dance with the European Medicines Agency  initiative on Important Medical Events, 
Boehringer Ingelheim has set up a list of further AEs, which by  their nature, can alway s be 
considered to be “serious” even though they  may  not have met the criteria of an SAE as given 
above.
The latest list of “Alway s Serious AEs” can be found in the RDC system . These events 
should alway s be reported as SAEs as described in Section 5. 3.7.
Adverse events o f special interest (AESIs)
The term AESI relates to any  specific AE that has been identified at the project level as being 
of particular concern for prospective safet y monitoring and safet y assessment within this trial, 
e.g. the potential for AEs based on knowledge from other compounds in the same class. AESI 
need to be reported to the Sponsor’s Pharmacovigilance Department within the same 
timeframe that app lies to SAE, see Section 5.3.7 .
The fol lowing are considered as AESIs: adverse events relating to gastrointestinal perforation 
and hepatic injury .
Hepatic Injury
In this stud y protocol, hepatic injury is defined as follows :
ALT and/or AST ≥ 8 fold ULN
ALTand /or AST ≥ 3 fold ULN and total bilirubin ≥ 2 fold ULN *
ALT and /or AST ≥ 3 fold ULN and unexplained INR > 1,5 *
ALTand /or AST ≥ 3 fold ULN and unexplained eosinophilia (>5%) *
ALT and /or AST ≥ 3 fold ULN and appearance of fatigue, nausea, vomiting, right 
upper abdominal quadrant pain or tenderness, fever and/or rash
* in the same blood draw sample.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 49of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015These lab findings constitute a hepatic injury  alert and the patients showing these l ab 
abnormalities need to be followed up according to the “DILI checklist” provided in the I SF.
In case of clinical s ymptoms of hepatic injury  (icterus, unexplained encephalopathy , 
unexplained coagulopathy , right upper quadrant abdominal pain, etc.) without lab results 
(ALT, AST, total bilirubin) available, the investigator should make sure these parameters are 
analysed, if necessary  in an unscheduled blood test. Should the results meet the criteria of 
hepatic injury  alert, the procedures described in the DI LI checklist should be followed .
Intensity of AEs
The intensity  of the AE should be judged based on the following:
Mild: Awareness of sign(s) or sy mptom(s) that is/are easily  tolerated
Moderate: Enough discomfort to cause interference with usual activity
Severe: Incapacitating or causing inability  to work or to perform usual activities
The intensity  of diarrhea adverse events should in addition be classified and recorded in the 
(e)CRF according to the Common Termin ology  Criteria for Adverse Events (CTCAE )
version 4 [R10-4848 ].
Table 5.3.6 .1:1 CTCAE Categorization for diarrhea
CTCAE Grade
1 Increase of <4 stools per day over baseline
2 Increase of 4 to 6 stools per day over baseline
3 Increase of ≥7 stools per d ay over baseline; incontinence
4 Life threatening consequences
5 Death
Causal relationship of AEs
The definition of an adverse reaction implies at least a reasonable possibility of a causal 
relationship between a suspected medicinal product and an adverse event. An adverse 
reaction, in contrast to an adverse event, is characterised b y the fact that a causal relationship 
between a medicinal product and an occurrence is suspected.
Medical judgment should be used to d etermine the relationship, considering all relevant 
factors, including pattern of reaction, temporal relationship, de -challenge or re -challenge, 
confounding factors such as concomitant medication, concomitant diseases and relevant 
history .
Arguments that m ay suggest that there is a reasonable possibility  of a causal relationship
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 50of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015could be:
• The event is consistent with the known pharmacology  of the drug
• The event is known to be caused b y or attributed to the drug class.
• A plausible time to onset of the event relative to the time of drug exposure.
• Evidence that the event is reproducible when the drug is re- introduced
• No medically  sound alternative aetiologies that could explain the event (e.g. 
preexisting or concomitant diseases, or co -medications).
•The event is ty pically  drug -related and infrequent in the general population not
exposed to drugs (e.g. Stevens -Johnson sy ndrome).
• An indication of dose -response (i.e. greater effect size if the dose is increased, 
smaller effect size if dose is diminish ed).
Arguments that may  suggest that there is no reasonable possibility  of a causal relationship
could be:
• No plausible time to onset of the event relative to the t ime of drug exposure is 
evident (e.g. pre- treatment cases, diagnosis of cancer or chro nic disease within days / 
weeks of drug administration; allergic reaction weeks after discontinuation of the drug 
concerned)
• Continuation of the event despite the withdrawal of the medication, taking into
account the pharmacological properties of the compound (e.g. after 5 half- lives).
Of note, this criterion may not be applicable to events whose time course is prolonged
despite removing the original trigger.
• Additional arguments amongst those stated before, like alternative explanation (e.g.
situati ons where other drugs or underl ying diseases appear to provide a more likely
explanation for the observed event than the drug concerned).
• Disappearance of the event even though the study drug treatment continues or 
remains unchanged.
For Japan only : The reason for the decision on causal relationship for unlisted AEs needs to 
be provided in the e CRF .
5.3.7 Adverse event collection and reporting
AE Collection
The Investigator shall maintain and keep detailed records of all AEs in their patient files.
The following must be collected and documented on the appropriate CRF(s) / eCRF by the 
Investigator:
•From signing the informed consent onwards through the Residual Effect Period 
(REP), until individual patient’s end of trial:
-all AEs (serious and non- serious) and all AESI s.
However, if an individual patient discontinues trial medication prematurel y but
stays in the trial (i.e. if further visits incl. telephone visits, or vital status assessments are 
planned) from then on and until the individual patient’s end of the trial the Investigator 
must report related SAEs and related AESIs.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 51of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015•After the individual patie nt’s end of trial: 
the investigator does not need to activel y monitor the patient for AEs but should only
report relevant SAEs and relevant AESIs of which the investigator may  become aware 
of.
The Residual Effect Period ( REP)is defined as 28days after the last trial medication 
application. All AEs which occurred through the treatment phase and throughout the REP 
will be considered as on treatment please see Section 7.3.4 . Events which occurred after the 
REP will be considered as post treatment events.
AE reporting to sponsor and timelines
The Investigator must report SAEs, AESI s, and non -serious AEs which are relevant for the 
reported SAE or AESI, on the BI SAE form via fax immediately  (within 24 hours ) to the 
Sponsor’s unique entry  point (country  specific contact details will be provided in the I SF). 
The same timeline applies if follow-up information becomes available. In specific occasions 
the Investigator could inform the Sponsor upfront via telephone. This does not replace the 
requirement to complete and fax the BI SAE form.
For Japa n only :All SAEs must be reported immediately  to the head of the trial site.
With receipt of an y further information to these events, a follow -up SAE form has to be
provided. For follow -up information the same rules and timeline apply  as for initial
information.
Information required
For each AE, the Investigator should provide the information requested on the appropriate 
(e)CRF pages and the BI SAE form . The Investigator should determine the causal 
relationship to the trial medication .
The following should also be recorded as an (S)AE in the (e)CRF and SAE form (if 
applicable):
Worsening of the underly ing disease or of other pre -existing conditions

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 52of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Changes in vital signs, ECG, phy sical examination and laboratory  test results, if they  
are judged clinically  relevant by  the Investigator.
If such abnormalities already  pre-exist prior trial inclusion they  will be considered as 
baseline conditions.
All (S)AEs, including those persisting after individual patient’s end of trialmust be followed 
up until they  have resolved, have been sufficiently  characterized, or no further information 
can be obtained.
Pregnancy
In rare cases pregnancy  may  occur in a clinical trial. Once a patient has been enrolled into
this clinical tria l and has taken trial medication, the Investigator must report immediately
(within 24 hours) a potential drug exposure during pregnancy  (DEDP) to the sponsor’s
unique entry point (country -specific contact details will be provided in the ISF). The
Pregnancy Monitoring Form for Clinical Trials (Part A) should be used.
The outcome of the pregnancy  associated with the drug exposure during pregnancy  must be 
followed up and reported to the Sponsor’s unique entry  point on the Pregnancy  Monitoring 
Form for Clinica l Trials (Part B). 
The I SF will contain the Pregnancy  Monitoring Form for Clinical Trials (Part A and B).
As pregnancy  itself is not to be reported as an AE, in the absence of an accompany ing SAE
and/or AESI , only the Pregnancy Monitoring Form for Clinical Trials and not the SAE form 
is to be completed. If there is an SAE and/or AESI associated with the pregnancy  anSAE
form must be completed in addition. 
 
 
 
 
 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 53of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015 
 
 
 
 
 
 
 
 
 
ASSESSMENT OF EXPLO RATORY BIOMARKER(S) 5.5
Blood samples will be taken according to theFlow Chart for the anal ysisof exploratory  
biomarkers. 
These samples will be stored for up to 3 years after the end of the clinical trial.
Samples will be shipped from the sites to a central laboratory  for short -term storage. These
samples will be shipped in batches from the central laboratory  to Boehringer Ingelheim or to
another location for biomarker anal yses or long -term storage.
In order to better understand the effects of nintedanib on the disease, mechanistic and disease 
related biomarkers will be assessed in peripheral blood of randomised patients.
The assessment of exploratory biomarkers is a key feature of this clinical trial wi th the aim to 
better characteris e and understand the disease, as well as their potential predicti ve value for 
treatment response. All b iomarkers related to IPFpathology  will be explored pre during and
post treatment with nintedanib or placebo in serum and plasma and will be correlated with the 
clinical endpoints.
 
 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 54of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015 
 
 
 
 
 
 
 
Methods and timing of sample col lection
Whole blood will be collected for the preparation of serum, plasma and  
Collection time points are outlined in the Flowchart and respective footnotes. Correct, 
complete and legible documentation of drug administration and blood sampl ing times is 
mandatory  to obtain data of adequate quality for biomarker anal ysis.
A detailed description of biomarker sample collection and sample handling is provided in the
ISF.
The samples will be shipped to the cen tral laboratory  and later anal ysed at the sponsor or a 
contractor of the sponsor. 
5.5.1 Analytical determinations
The anal ytical methods for the anal ysis of biomarkers from blood will be given in detail in a 
analytical biomarker report.
5.5.2 Biobanking
To allow for future scientific anal yses, all pat ients will be asked for additional samples. Only  
if a separate specific informed consent is given in accordance with local ethical and 
regulatory  requirements, DNA and/or serum banking samples will be taken, processed and 
stored. Participation in the DNA and/or serum banking part is voluntary  and not a 
prerequisite for participation in the study .

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 55of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Serum banking
To enable future not yet specified biomarker analy ses additional blood will be collected into 
serum collection tubes. This sample will be collected according to the Flow C hart. Details on 
sample collection and processing will be given in the I SF. This sample will be stored up to 15 
years after th e end of the trial and may  be used for further characterization of I PF patients.
Approximately  100 mL of blood will be collected for serum banking.  Detailed instructions 
for serum banking sampling, handling and shipment of samples are provided in the I SF.
DNA banking
The DNA sample derived from the original blood sample will be stored b y Boehringer
Ingelheim for up to 15 years after the end of the clinical trial or until there is no more 
material available for tests. The stored DNA may  be used at a later time for 
pharmacogenomic anal yses.  
Methods and timing of DNA banking sample collection
An amount of approximately  8.5 mL blood will be collected per PaxGene DNA blood 
sampling tube for those patients who signed a separate informed consent concerning the
Sample DNA banking part with any  other blood sampling after randomis ation. The Paxgene 
Blood DNA tubes can be stored and shipped at room temperature within 14 days. If a longer 
storage and shipment period for Paxgene Blood DNA tubes is necessary , the bloo d samples 
have to be stored at a temperature of approximately  -20°C or below.
Once frozen, thawing of the samples should be avoided except for analy sis.
Detailed instructions for pharmacogenomics sampling, handling and shipment of samples are
provided in t he ISF.
OTHER ASSESSMENTS 5.6
Not applicable.
APPROPRIATENESS OF M EASUREMENTS 5.7
All measurements conducted in the trial are using standard methods.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 56of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20156. INVESTIGATIONAL PLAN
VISIT S CHEDULE 6.1
This trial starts with Visit 0 during which informed consent process shall be undergone 
HRCT scans and biopsies (later if available) shall be sent for central review to confirm the 
diagnosis of IPF. Further the trial consists of screening visit (Vi sit 1) and screening period
lasting 14 days (2 weeks) ,treatment period lasting52 weeks and follow -up period lasting 28 
days(4 weeks) . The treatment period will consist of two parts. A t Visit 2 p atients will be 
randomised into double -blind portion of the study. Additional clinic visits of the double blind 
period will be scheduled at week 4, 8 and 12 (Visits 3, 4 and 5 ). At Visit 5 , i.e. after 
completing the randomis ed, double blind treatment all patients will enter the single ar m, open 
label, active treatment period. During this period patients will visit the clinic for scheduled 
visits at week 1 6, 20, 24, 36 and 52 (Visits 6, 7, 8, 9 and 10). The follow- up visit 
(Visit 1 1) 
will be scheduled 2 8days post -treatment. Unscheduled vi sits may  be conducted anytime if 
deemed necessary .
Time windows to be adhered to for scheduling of visits are shown in the Flow Chart . Site s 
should make every  attempt to adhere to the protocol time windows as close as possible. The 
screening period (between Visit 1 and Visit 2) may be extended by  additional 2 week s(i.e. 28 
day total) for anyreasons (e.g. exacerbation, lab results receipt , etc. ). All onsite visits from 
Visits 1 to Visit 1 1willbe scheduled in the morn ing, in order to guarantee start of pulmonary  
function testing at approximately  the same time of the day  (recommended time for PFTs from 
8:00 till 11.00 a.m. ; any  subsequent PFTs shou ld preferabl y be done within ± 90 minutes 
from t he measurement at Visit 1 ). Patients should make every  attempt to complete the study  
as specified. Investigators should encourage patient treatment compliance and adherence to 
other protocol specific activities.
All deviations from the planned visit schedu le will be documented. 
Rescheduling prior to randomisation.
• if a patient experiences a cute IPFexacerbation or respiratory  tract infection between Visit 0 
and Visit 1, the Visit 1 will be postponed until complete recovery  from the infection or 
exacerbat ion, preferabl y 4 weeks following the recovery  from the infection or exacerbation .
• laborato ry parameters found abnormal at visit 1 may  be re -tested once prior to Visit 2.
• if the screening period (2 weeks and 2 additional weeks for administrative reason s)needs to 
beextended further (counted from Visit 1), the clinical monitor should be contacted.
Reasoned prolongation of the screening period may be allowed b y the clinical monitor.
• if a patient experiences an IPFexacerbation or respiratory  tract infection during the 
screening period ( 2 weeks ) between Visit1 and Vis it 2, the Visit 2 will be postponed until 
complete recovery  from the infection or exacerbation , preferabl y 4 weeks following the 
recovery  from the infe ction or exacerbation .
Patients should make every  attempt to adhere to the protocol. Investigators should encourage 
patient treatment compliance and adherence to other protocol related activities.
Subsequent visits should alway s be planned to take place at scheduled dates in line with the 
protocol Flow Chart .
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 57of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015DETAILS OF TRIAL PRO CEDURES AT SELECTED VISITS 6.2
6.2.1 Screening and run -in period(s)
Visit 0
Informed c onsent will be obtained prior to patient participation in the trial, which includes 
any study  related procedures, medication washout procedures or restrictions. Furthermore, 
the patient will be asked to give informed consent to the pharmacogenomic (optiona lDNA 
and serum banking sample ) anal yses. HRCT and biopsy  tissue samples ( later if available) 
shall be sent for central review. Call the IRT to register a new patient into the study .
Visit 1
Visit 1 may  only  be performed once the central HRCT and biopsy  tissue sample reading 
confirm the IPF diagnosis
At Visit 1:
-Verif y medication washout compliance
-Record demographic data 
-Conduct relevant medical history  and ph ysical examination including height and weight
measurements , vital signs (blood pressure an d pulse rate), pulse oximetry  (Sp0 2)and 12 -lead 
ECG. The vital signs (seated) , pulse oximetry and ECG should be conducted following five 
minutes rest and prior to screening pulmonary  function testing and DLCO measurement
-Perform blood collections for haematology , serum chemistry , coagulation panel and urine 
pregnancy  test (if applicable) . Blood samples shall be sent to central laborator y;for further 
information refer to Laboratory Manual in the ISF
-Perform pulmonary function testing in the morn ing preferabl y between 08:00 – 11:00. 
Patients must demonstrate FVC ≥ 80% to be eligible .
-Perform DLCO measurement
-Review and record all adverse events experience d since signed informed consent
-Record concomitant therapy  for the previous 3 months in the eCRF as described in Section 
4.2. 
-Review i nclusion and exclusion criteria
-Instruct and train patients on how to perform and record PFTs at home
- Give instructions on medication restrictions and washout requirements for the screening 
period and subsequent visits
-Instruct patients to bring all stud y-related equipment to the clinic at each visit
- Sche dule the next clinic visit in 14 day s (2weeks) , additional 2 weeks are allowed for 
administrative reasons
Screening period

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 58of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015 
 
 
 
6.2.2 Treatment period(s)
The order of procedur es should be as follows: patient self- administered questionnaires (if 
applicable), blood collections (as per Flow Chart ), vital signs and ECG (if applicable), PFTs, 
medication administration (if applicable) .  
Observations / Procedures
Visit 2 (randomisation visit)
Optional -Call the patient the day  before the clinic visit to remind the clinic visit next day . 
Remind the patient medication washout re quirements (if applicable) and to bring all study  
related supplies (home spirometer) to the clinic visit. 
 
 
-Review and record all adverse event s experienced and changes in concomitant therapy .
-Review all inclusion and exclusion criteria
-Perform blood collections for haematology , serum chemistry , coagulation panel and urine 
pregnancy  test (if applicable) including biomarker serum and plasma sa mples, biomarker 
RNA sample, optional serum banking sample and optional DNA banking sample if 
applicable (later sample may  be collected at any  time as of Visit 2). For further details on 
safet y lab collections refer to Section 5.3.3 . For further details on biomarker related 
collections refer to Section 5.5 . Blood samples sha ll be sent to central laborator y;for further 
information follow Laboratory Manual in the ISF
-Record vital signs (blood pressure and pulse rate) before PFTs and with the patient seated 
and r ested for at least five minutes
-Record patient weight
-Perform supervised PFTs
-Perform randomisation in case patient is eligible 
-Call I RTto randomise the patient and dispense the first blinded medication kit (period 
between Visit 2 and Visit 3) 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 59of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015- Instruct patient to take the first capsule at the clinic under trial staff supervision. Refer to 
Section 4.1.4 .Instruct patient on further medication intake, please refer to Section 4.2
regarding possible dose reductions, interruptions and m anagement of drug relates AEs
-Dispense the Patient Diary  and instruct the patient on its use 
-Schedule next planned clinic visit. Instruct patients to bring all study related trea tments to 
the next clinic visit
Visit s3 and 4  
Optional -Call the patient the day  before the clinic visit to remind the clinic visit next day . 
Remind the patient medication washout requirements (if applicable) and to bring all study  
related supplies (home spirometer, patient diary , treatments , etc.) to the clinic visit. 
 
-Review and discuss new Patient Diary  entries with the patient 
-Review and record all adverse events experienced and changes in concomitant therapy
-Perform blood collection sand urine pregnancy  test (if applicable) . Refer to Section 5.3.3  
- Collect biom arker serum and plasma samples ,optional serum banking sample and optional 
DNA banking sample if applicable (later sample may  be collected at any  time as of Visit 2). 
Refer to Section 5.5
 
- Record vital signs (blood pressure and pulse rate) before PFTs and with the patient seated 
and re sted for at least five minutes (at Visit 3 only)
-Record patient weight
-Perform supervised PFTs
- Per form Study  Drug Compliance Check
-Call IRTto dispense the blinded medication kits (for further details refer to Section 4.1.4)
-Administer morning dose of the trial drug from newly  dispensed kit at the site 
-Schedule n ext planned clinic visit. I nstruct patients to bring all study related trea tments to 
the next clinic visit

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 60of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Visit 5  
Optional -Call the patient the day  before the clinic visit to remind the clinic visit next day . 
Remind the patient medication washout requirements (if applicable) and to bring all study  
related supplies (  patient diary , treatments , etc.) to the clinic visit.
 
 
-Review and discuss new Patient Diary  entries with the patient 
-Review and record all adverse events experienced and changes in concomitant therapy
-Record vital signs (blood pressure and pulse rate) before PFTs and with the patient seated 
and re sted for at least five minutes
-Record patient weight
-Perform safet y laboratory collections and urine pregnancy  test (if applicable). For further 
details refer to Section 5.3.3
-Collect biom arker serum and plasma samples ,optional serum banking sample and optional 
DNA banking sample if applicable (later sample may  be collected at any  time as of Visit 2). 
Refer to Section 5.5
 Section 5.5
-Perform supervised PFTs
-Perform Study  Drug Compliance Check
-Call IRTto dispense the open label medication kits (for furthe r details refer to Section 4.1.4 ) 
-Instruct patient to take the first capsule of open label medication at the clinic under trial 
staff supervision. Refer to Section 4.1.4 Instruct patient on further medication intake, please 
refer to Section 4.2 regarding possible dose reductions, interruptions and management of drug 
relates AEs.
-Schedule next planned clinic visit. I nstruct patients to bring all study  related treatments to 
the n ext clinic visit.
Visit s 6, 7 , 8 and 9   
Optional - Call the patient the day  before the clinic visit to remind the clinic visit next day . 
Remind the patient medication washout requirements (if applicable) and to bring all study  
related supplies ( , patient diary , treatments , etc.) to the clinic visit.
 
-Review and discuss new Patient Diary  entries with the patient
-Review and record all adverse events experienced and changes in concomitant therapy

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 61of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015- Record vital signs (blood pressure and pulse rate) before PFTs and with the patient seated 
and res ted fo r at least five minutes (Visit 6, 8 and 9 )
-Record patient we ight
-Perform safet y laboratory collections and urin e pregnancy  test. For further details refer to 
Section 5.3.3 .
- Collect biom arker serum and plasma samples ,optional serum banking sample and optional 
DNA banking sample if applicable (later sample may  be collected at any  time as of Visit 2). 
Refer to Section 5.5
 
 
-Perform supervised PFTs.
-Perform Study  Drug Compliance Check
-Call IRTto dispense the open label medication kits (for further details refer to Section 4.1.4 ) 
(not applicable at Visit 6 and 7 )
-Administer morning dose of the trial drug from the newl y dispensed kits at the site (not 
applicable at Visit 6 and 7, as kits dispensed at Visit 5 will be used at these visits)
-Schedule next planned clinic visit. I nstruct patients to bring all study related trea tments to 
the next clinic visit
Visit 10(End of treatment visit)
Optional - Call the patient the day  before the clinic visit to remind the clinic visit next day . 
Remind the patient medication washout requirements (if applicable) and to bring all study  
related supplies (home spirometer, patient diary , treatments , etc.) to the clinic visit.
 
-Review and discuss new Patient Diary  entries with the patient 
-Review and record all adverse events experienced and changes in concomitant therapy
-Perform blood collections for haematology , serum chemistry , coagulation panel and urine 
pregnancy test (if applicable), including biomarker serum and plasma samples, biomarker 
RNA sample, optional serum banking sample and optional DNA banking sample if 
applicable (later sample may  be collected at any  time as of Visit 2). For further details on 
safet y lab collections refer to Section 5.3.3 . For further details on biomarker related 
collections refer to Section 5.5 . Blood samples shall be sent to central laboratory; for further 
information follow Laboratory Manual in the ISF .
 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 62of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015 
-Perform physical examination including vital signs (blood pressure and pulse rate) and 
perform 12-lead ECG before PFTs with the patient s eated and rested for at least five minutes. 
-Record patient weight
-Perform supervised PFTs
-Perform Study  Drug Compliance Check
- Administer the last morning dose of the trial drug at the site . Collect remaining study  drug. 
After the last dose of trial medication the Investigator /the treating ph ysician may initiate 
further IPF treatment in line with the protocol Section 4.2.2 . 
-Call I RTto record End of Treatment
 
-Schedule next planned clinic visit (the Follow -up visit) . Instruct patients to bring all 
remaining study  supplies to the next clinic visit
6.2.3 Follow Up Period and Trial Completion
Visit 11 (Follow -up Visit) 
Patients will be contacted once at the end of the follow up period. A dverse events and 
concomitant therapies will be reviewed and recorded. Urine pregnancy  test will be performed 
in applicable patients. A 12 -lead ECG and ph ysical examination including vital signs should 
be performed if these were abnormal at Visit 10. R emaining trial supplies should be collected.
Premature withdrawal
Patient s who prematurel y discontinue study  drugs (refer to Section 3.3.4 ) before the planned 
end of treatment at Visit 10 , should come to the clinic as soon as possible after last drug 
intake for an earl y EOT visit. Reason for discontinuation must be documented in the eCRF. 
For detailed description of the trial procedures at this visit, please refer to the Flow C hart. 
In addition patients will be invited to attend all remaining planned visits and perform all 
study  procedures  If a patient doesn’t accept to attend 
remaining stud y visits, collect the home spirometer and an y trial related supplies and contact 
patient for vi tal status collection at week 52 .The need tocome to remaining scheduled visits 
in case of prematurely  discontinuation of trial medication will be explained to patients prior 
to the irparticipation in the trial . 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 63of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Vital status information
In case of an early discontinuation of trial medication, if the patient does not agree to come to 
future visits as planned, anyattempt will be made to get information on vital status at Week 
52 (refer to Flow Chart ).
Patients will be asked to agree to be contacted b y the site personnel, w hich could be by  
telephone calls, to allow collection of this information.
If death occurs, the investigator will review the circumstances, including the relevant medical 
records to ascertain the most likely  primary  and secondary  causes of death.
Collectio n of vital status will be performed in accordance with national ethical and regulatory  
guidelines. The need for vital status information will be explained to patients prior to their 
participation in the trial.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 64of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20157. STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
STATISTICAL DESIGN - MODEL 7.1
This is a randomi sed, placebo controlled, multi -centre, multinational , prospective, double 
blind trial to investigate the effect of oral nintedanib 150 mg twice daily  on change in 
biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary  
fibrosis (I PF) and preserved forced vital capacit y (FVC) .
The primary  endpoint is the rate of change (slope) in blood CRPM from baseline to week 12. 
Therefore, the rate of change (slope) in blood CRPM will be analy zed using random 
coefficient regression (random slopes and intercepts) model including gen der, age and height
as covariates.
The secondary  endpoint, proportion of patients with disease progression defined by  FVC 
decline ≥10% or death, will be analysed using logistic regression models or other appropriate 
methods .
NULL AND ALTERNATIVE HYPOTHESES 7.2
The objective of this study , demonstrating a treatment effect of nintedanib at a dose of 150 
mg bid compared to placebo for the rate of change (slope) in blood CRPM , will be tested 
using the following null hy pothesis.
H0: No difference in the rate of change (slope) in blood CRPM evaluated from 
baseline until 12 weeks of treatment between nintedanib mg bid and placebo.
The alternative hy pothesis is
Ha: The rate of change (slope) in blood CRPM isdifferent for patients taking 
nintedanib 150 mg bid than those taking placebo.
The hy pothes is will be tested using 5% level of significance (two -sided test).
PLANNED ANALYSES 7.3
The statistical anal ysis will be bas ed on the following populations.
Treated Se t(TS) :
The treated set (TS) consists of patients who are randomi sed to a treatment group and
receive at least one dose of study  medication
Randomised Set (RS):
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 65of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015The Randomised set (RS), consists of those patients who were randomis ed to a
treatment group.
 
 
The efficacy  and safet y analysis will be conducted on the TS. Efficacy  parameters will be 
analysed from an as randomised per spective and safet y parameters from an as treated 
perspective, respectivel y. For efficacy  analy sis,all measurement performed within the first 12 
weeks will be used. Efficacy  evaluations done after lung transplant will not be used for the 
efficacy  anal yses; sensitivity  anal yses will be performed including these data.
Although there is no per protocol data set in the study , reasons for important protocol
violations will be specified in the Trial Statistical Analy sis Plan (TSAP). Patients wit h 
potential important protocol violations (those that relate to patient safet y or efficacy) will be 
identified at Blinded Review Planning Meetings and listed in the clinical trial report .
7.3.1 Primary endpoint analyses
The primary  endpoint is the rate of change (slope) in blood CRPM evaluated from baseline 
over 12 weeks (expressed in ng/mL /month) estimated from measurements taken over 12 
weeks of treatment. The rate of change (slope) in blood CRPM is assumed to be linear within 
each subject over the 12 weeks period . The intercepts and slopes will be assumed to be 
normally  distributed with arbitrary  covariance matrix. Gender, age and height whi ch are usual 
predict ors of FVC will also be included in the model. Baseline blood CRPM will be 
measured at visit 2. No imputation is planned if this assessment is not available for a patient. 
The within patient error will be assumed to be independent and normally  distributed with 
mean zero and a common variance. The Kenward -Roger approximation will be used to 
estimate denominators degrees of freedom. Significan cetests will be based on least- squares 
means using a two-sided α=0.05 ( two-sided 95% confidence intervals). Analy ses will be 
implemented using SAS® Version 9.4.
The linearit y assumption for the rate of change (slope) in blood CRPM w ill be tested and 
sensitivity  anal ysis will be done with alternative models described in the Trial Statistical 
Analy sis Plan (TSAP). The effe ct of missing data will be investigated using pattern- mixture 
models. Depending on the pattern of the missingness in the data, multiple imputation 
methods may  also be considered.
 
7.3.2 Secondary endpoint analyses
For the key secondary  endpoint, proportion of patients with disease progression as defined by  
FVC decline ≥10% or death over week 52, two main anal yses are planned. 
Firstly , in order to assess the predictive value of change in extracellular matrix (ECM) 
biomarker CRPM over 12 weeks fordisease progression as defined b y FVC decline ≥10% or 

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 66of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015death over 52 weeks , a logistic regression (or a similar appropriate) anal ysis including 
baseline blood CRPM and the rate o f change (slope) in blood CRPM over the first 12 weeks 
as covariates will be applied for the placebo treated patients only .
Secondly , in order to assess how nintedanib treatment during the first 12 weeks affects the 
association between change in extracellu lar matrix (ECM) biomarker CRPM over 12 weeks 
and disease progression , a logistic regression (or a similar appropriate) analy sis including 
baseline blood CRPM , rate of change (slope) in blood CRPM over the first 12 weeks , 
treatment and treatment CRPM slope interaction as covariates will be applied. The interaction 
term will be of primary  interest within this analy sis.More details will be given in the TSAP.
Both anal yses will be repeated for rate of change (slope) in the biomarkers C1M and C3M 
defined as se condary  endpoints. Reasonably , baseline CRPM as covariate will be replaced by  
baseline C1M/C3M in these anal yses.
7.3.4 Safety analyses
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA) coding dictionary . Standard BI summary  tables and listings will be produced. All 
adverse events with an onset between start of treatment and end of the residual effect period 
(REP), a period of 28 days 
after the last dose of trial medication, will be assigned to the t reatment period for evaluation.
All treated patients will be included in the safet y analysis. In general, safet y anal yses will be 
descriptive in nature and will be based on BI standards. No h ypothesis testing is planned.
Statistical analy sis and reporting of adverse events will concentrate on treatment -emergent 
adverse events. To this end, all adverse events occurring between start of treatment and end 
of the residual effect period will be considered ‘treatment-emergent’.  The residual effect 
period is defined as 28 day s. Adverse events that start before first drug intake and deteriorate 
under treatment will also be considered as ‘treatment- emergent’.

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 67of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Frequency , severit y, and causal relationship of adverse events will be tabulated b y system 
organ class and preferred term after coding according to the current version of the Medical 
Dictionary  for Drug Regulatory  Activities (MedDRA).
Laboratory  data will be analy sed both quantitatively  as well as qualitatively. The latter will 
be done via comparison of laboratory data to their reference ranges. Values outside the 
reference range as well as values defined as clinicall y relevant will be highlighted in the 
listings. Treatment groups will be compared descriptively  with regard to distribution 
parameters as well as with regard to frequency  and percentage of patients with abnormal 
values or clinicall y relevant abnormal value s.
Vital signs, ph ysical examinations, or other safety- relevant data observed at screening, 
baseline, during the course of the trial and at the end -of-trial evaluation will be assessed with 
regard to possible changes compared to findings before start of treatment.
 
 
 
 
INTERIM ANALYSES 7.4
No interim anal ysis is planned.
HANDLING OF MISSING DATA 7.5
7.5.1 Efficacy endpoints
In efficacy  anal yses of continuous endpoints ,missing data will not be imputed. In the 
analysesof the time-to-event endpoints, missing or incomplete data are managed b y standard 
survival analysis techniques. These will be described in detail in the TSAP.
In the anal yses of the categorical endpoints, missing data will be imputed using the worst 
case.

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 68of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20157.5.2 Safety endpoints
Missing or incomplete AE dates will be imputed according to BI standards . With respect to 
other safet y evaluations, it is not planned to impute missing values.
 
RANDOMISATION 7.6
Patients will be randomis ed in blocks to double -blind treatment with an unequal probability  1
to 2of assignment to nintedanib and placebo . BI will arrange for the randomis ation and the 
packaging and labelling of trial medication. The randomi sation list will be generated using a 
validated sy stem, which involves a pseudo -random number generator so that the resulting 
treatment will be both reproducible and non -predictable. The block size will be documented 
in the CTR. Access to the codes will be controlled and documented. All members of the 
Medical Project Team will remain blinded to the randomi sation schedule until after the final 
database is locked .
DETERMINATION OF SAM PLE SIZE 7.7
The sample size calculations are based on change relative to baseline in biomarker levels of 
serum CRPM, serum C1M andserum C3M (unpublished data, no reference available) . The 
sample size calculations are based on two -sided tests ( α=0.05) to detect a difference in 
means of two independent samples with a 1:2 randomisation ratio nintedanib:plac eboin the 
samples with a power of 90%. No multiplicity  adjustments are made as part of the power 
calculation, and no adjustment is made for a potential subject withdrawal. Sample size 
calculations are performed for assumed differences between treatment gr oup and placebo of 
20% and 30% difference. Due to the lack of data from respective IPF patients and since there 
is no evidence biomarker courses are principally  different across both indications, data from 
two studies of RA patients are used to estimate th e standard deviation over time in biomarker 
values relative to baseline: Study  A) RA patients including a placebo group and a treatment 
group with measurements of serum CRPM, serum C1M and serum C3M at baseline, weeks 4, 
16, and 24; and Study  B) RA patients including a placebo group and a treatment group with 
measurements of serum CRPM, serum C1M and serum C3M at baseline, weeks 4, and 12.
The hy pothesis to be tested can be formulat ed as:
H0: µ Treatment = µ Placebo
tested confirmativel y against the alternative
Ha: µ Treatment     µPlacebo
where µTreatment is the change in biomarker relative to baseline in the treatment group, and 
µPlacebo is the change relative to baseline in the placebo group.

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 69of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Table 7.7:1 Data of standard deviation over time in changes relative to baseline
Data of standard deviation over time in changes relative to baseline 
CRPM C1M C3M
Placebo Treatment Placebo Treatment Placebo Treatment
Study  A
Week 442%
(n=100)34%
(n=143)44% 
(n=116)41% 
(n=176)38% 
(n=116)31% 
(n=176)
Week 1633% 
(n=88)36% 
(n=128)42% 
(n=102)58% 
(n=156)32% 
(n=102)27% 
(n=156)
Week 2431% 
(n=83)32% 
(n=131)53% 
(n=97)53% 
(n=162)33% 
(n=97)31% 
(n=162)
Study  B
Week 440% 
(n=71)25% 
(n=66)48%
(n=76)68%
(n=75)43% 
(n=71)66% 
(n=67)
Week 1243% 
(n=52)47% 
(n=68)45% 
(n=54)55% 
(n=73)44% 
(n=50)44% 
(n=68)
Based on Table 7.7:1, sample sizes will be calculated for a range of common standard 
deviations of 30%; 40% and 50%.
Table 2 gives the calculated sample size numbers for assumed relative treatment differences 
of 20 and 30 percent.
Table 7.7:2 Sample sizes for common standa rd deviations of 30%, 40%, and 50%; 
significance level 5%; power 90% with a 1:2 randomisation ratio 
nintedanib:placebo
Sample sizes for common standard deviations of 30%, 40%, and 50%; significance level 
5%; power 90% with a 1:2 randomisation ratio nintedanib:placebo
Common STD 30% Common STD 40% Common STD 50%
n n n
nintedanib placebo total nintedanib placebo total nintedanib placebo total
20% 37 73 110 64 128 192 100 199 299
30% 17 33 50 29 58 87 45 89 134
If thetrue standard deviation of change in CRPM relative to baseline lies between 30 and 50 
percent , a total number of patients between 110 and 300 would be needed to detect a 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 70of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015treatment group difference of 20% with a power of 90% with a treatment allocation ratio of 
1:2 (Nintedanib:Placebo) .
However, the key secondary  endpoint requires more patients for two reasons: firstly , only 
patients initially  treated with Placebo are analy sed in the first step (reducing the actual sample 
size for thisanalysis to 2/3 of t he total sample size) and secondly , some loss of information is 
associated with theplanned analy sis due to the binary  state of the endpoint. To be more 
precise, with n=350 randomised patients, n=233 patients will be initially  treated with Placebo
and based on theINPULSI Sresults [P14-07514 ], we expect to observe a total of about 40% 
of disease progression as defined by FVC decline ≥10% or death over week 52 for that 
treatment group. Using available datafrom theobservational PROFILE study  [R15 -1220] , 
we further expect roughly half of thepatients to have rising biom arker values (slope greater 
than zero) andthe remaining patients having stable biomarker values (slope less or equal to 
zero) resulting in about equally  sized groups if the rate of change (slope) in blood CRPM 
from baseline to week 12 is dichotomized. With the stated sample size, a n absolute difference 
in rates of at least 20% (i.e. 30% vs 50% of patients with disease progre ssion) can be detected 
with a power of 88%. 
For these reasons , a sample size of n=350 patients (117 on nintedanib and 233 on placebo) is 
planned for this study .
Calculations were performed using nQuery  Advisor® 6.1 .1statistical package b y Statistical 
Solutions L td.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 71of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20158. INFORMED CONSENT, DA TA PROTECTION, TRIAL
RECORDS
The trial will be carried out in accordance with the Medical Devices Directive (93/42/EEC) 
and the harmonized standards fo r Medical Devices (I SO 14155 current version ).
The trial will be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the I CH Harmonized Tripartite Guideline 
for Good Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs), the
EU regulation 536/2014 the Japanese GCP regulations (Ministry  of Health and Welfare 
Ordinance No. 28, March 27, 1997) and other relevant regulations .
Standard medical care (prophy lactic, diagnostic and therapeutic procedures) remains in the 
responsibilit y of the treating phy sician of the patient.
The Investigator will inform the Sponsor immediately  of any  urgent safety measures taken to 
protect the trialsubjects against any  immediate hazard, and also of an y serious breaches of 
the protocol or of ICH GCP .
The rights of the Investigator and of the Sponsor with regard to publication of the results of 
this trial are described in the Investigator contract. As a rule , no trial results should be 
published prior to finalization of the Clinical Trial Report.
For Japan only :The rights of the investigator / trial site and of the sponsor with regard to 
publication of the results of this trial are described in the investigator contract / trial site’s 
contract. As a general rule, no trial results should be published prior to finalisation of the 
Clinical Trial Report.
The certificate of insurance cover is made available to the Investigator and the patients , and is
stored in the I SF (Investigator Site File ).”
TRIAL APPROVAL, PATIENT IN FORMATION, AND INFOR MED 8.1
CONSENT
This trial will be initiated only  after all required legal documentation has been reviewed and 
approved b y the respective Institutional Review Board (IRB) / Independent Ethics Committee 
(IEC) and competent authority  (CA) according to national and internati onal regulations. The 
same applies for the implementation of changes introduced by  amendments.
Prior to patient participation in the trial, written informed consent must be obtained from each 
patient according to ICH GCP and to the regulatory  and legal req uirements of the 
participating country . Each signature must be personally  dated by  each sign atory  and the 
informed consent and any  additional patient -information form retained by  the Investigator as 
part of the trial records. A signed cop y of the informed consent and an y additional patient 
information must be given to each patient or the patient’s legall y accepted representative.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 72of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015For Japan only : The Investigator must give a full explanation to trial patients including the 
items listed below in association w ith the use of the patient information form, which is 
prepared avoiding the use of technical terms and expressions. The patient is given sufficient 
time to consider participation in the trial. The I nvestigator obtains written consent of the 
patient’s own free will with the informed consent form after confirming that the patient 
understands the contents. The Investigator must sign (or place a seal on) and date the 
informed consent form. If a trial collaborator has given a supplementary  explanation, the trial
collaborator also signs (or places a seal on) and dates the informed consent.
Re-consenting may  become necessary  when new relevant information becomes available and 
should be conducted according to the sponsor’s instructions.
DATA QUALITY ASSURANC E 8.2
A quality  assurance audit/inspection of this trial may  be conducted by  the Sponsor, Sponsor’s 
designees, or b y IRB / IEC or by  regulatory  authorities. The quality  assurance auditor will 
have access to all medical records, the Investigator’s trial -related files and correspondence, 
and the informed consent documentation of this clinical trial.
To ensure good quality  data, investigators and study  site personnel will be familiarized with 
the study  protocol, pro cedures and principles of GCP during the investigator meeting and/or 
trial initiation visit. An ISF with all necessary  trial related documentation and handling 
procedures will be provided. 
A central laboratory  will be used for anal ysis of all bl ood sample s. 
To ensure standardization in FVC measurement, a centr al spirometry  review will be in place. 
Spirometry  devices will be supplied to all participating sites /patients . 
Data will be captured using a nRDC system. Training will be provided to all investigators, 
coordinators and CRAs to ensure consistency  and accuracy  of the data. The data will be 
source verified b y the CRA during regular onsite monitoring. 
Data management procedures to ensure the quality of the data are described in detail in the 
trial data management and anal ysis plan which is available in the TMF.
Coding of concomitant medications is according to the World Health Organisation drug 
dictionary  and coding of AEs is according to the MedDRA dic tionary .
RECORDS 8.3
Electronic Case Report Forms (eCRF )for individual patients will be provided by  the Sponsor. 
See Section 4.1.5.2 for rules about emergency  code breaks. For drug accountab ility, refer to 
Section 4.1.8 .
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 73of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20158.3.1 Source documents
Source documents prov ide evidence for the existence of the patient and substantiate the 
integrit y of the data collected. Source documents are filed at the Investigator ’s site.
Data reported on the CRF must be consistent with the source data or the discrepancies must 
be explained. The Investigator may  need to request previous medical records or transfer 
records, depending on the trial; current medical records must also be available.
8.3.2 Direct access to source data and documents
The Investigator / institution will permit trial -related monitoring, audits, I RB / IEC review 
and regulatory  inspection, providing direct access to all related source data / documents. 
eCRF and all source documents, including progress notes and copies of laboratory  and 
medical test results must be available at all times for review b y the Sponsor’s clinical trial 
monitor, auditor and inspection by  health authorities (e.g. FDA). The CRA / on site monitor 
and auditor may  review all CRF / eCRF, and written informed consents. The accuracy  of the 
data will be verified b y reviewing the docu ments described in Section 8.3.1.
8.3.3 Storage period of records
For Japan only :
Trial site(s):
The trial site(s) must retain the source and essential documents (including ISF) according to 
national or local requirements (whatever is longer) valid at the time of the end of the trial .
Sponsor:
The Sponsor must retain the essential documents according to the Sponsor ’s SOPs.
LISTEDNESS AND EXPED ITED REPORTING OF AD VERSE EVENTS 8.4
8.4.1 Listedness
To fulfil the regulatory  requirements for expedited safet y reporting, the Sponsor evaluates 
whether a particular AE is "listed", i.e. is a known side effect of the drug or not. Therefore, a 
unique reference document for the evaluation of listedness needs to be provided. For 
nintedanib this is the current version of the IB (c01805141-17) . 
The current versions of these reference documents are provided in the I SF. No AEare 
classified as listed for trial design, or invasive procedures .
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 74of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20158.4.2 Expedited reporting
BI is responsible to fulfil their legal regulatory  reporting obligation and in accordance to the
requirements defined in this CTP.
STATEMENT OF CONFIDE NTIALITY 8.5
Individual patient medical information obtained as a result of this trial is considered 
confidential and disclosure to third parties is prohibited with the exceptions noted below. 
Patient confidentiality  will be ensured by  using patient identification code numbers.
Treatment data ma y be given to the patient’s personal physician or to other appropriate 
medical personnel responsible for the patient’s welfare. Data generated as a result of the trial 
need to be available for inspection on request b y the participating ph ysicians, the Sponsor ’s 
representatives, b y the IRB / IEC and the regulatory authorities .
END OF TRIAL 8.6
The end of the trial is defined as the date of the last visit of the last patient in the whole trial 
(“Last Patient Out”). 
The IEC/competent authority  in each participating EU member state will be notified about 
the end orearly termination of the trial.
For Japan only : 
When the trial is completed, the Investigator should inform the head of the trial site of the 
completion in writing, and the head of the trial site should promptly  inform the I RB and 
Sponsor of the completion in writing.
PROTOCOL VIOLATIONS 8.7
For Japan onl y:The investigator should document any  deviation from the protocol regardless 
of their reasons. Only when the protocol was not followed in order to avoid an immediate 
hazard to trial subjects or for other medically  compelling reason, the principal investi gator 
should prepare and submit the records explaining the reasons thereof to the sponsor, and 
retain a cop y of the records.
COMPENSATION AVAILAB LE TO THE PATIENT IN THE EVENT OF 8.8
TRIAL RELATED INJURY
For Japan only :In the event of health injury associated with this trial, the Sponsor is 
responsible for compensation based on the con tract signed by  the trial site.
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 75of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan20159. REFERENCES
PUBLISHED REFERENCES 9.1
P05-02699 King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz 
DA. Anal yses of efficacy end points in a controlled trial of interferon-
gamma1b for idiopathic pul monary fibrosis. Chest 127 (1), 171 -177 (2005)
P05-12782 Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo 
R, Enright P, Grinten CPM van der, Gustafsson P, Jensen R, Johnson DC, 
MacInt yre N, McKay  R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, 
Wanger J . Standardisation of spirometry .Eur Respir J 26 (2), 319 -338 (2005)
P08-08684 Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch -
Grunt U, Garin -Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and 
good antitumor efficacy .Cancer Res 68 (12), 4774 -4782 (2008)
P11-00203 Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P,
Pawel J von . A phase II double -blind study  to in vestigate efficacy  and safety  
of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with 
relapsed advanced non -small
-cell lung cancer. Ann Oncol 22 (6), 1374 –1381
(2011)
P11-07084  Raghu G, et al, ATS/ERS/JRS/AL AT Committee on I diopathic Pulmonary 
Fibrosis .  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary  
fibrosis: evidence -based guidelines for diagnosis and management. Am J 
Respir Crit Care Med 183 (6), 788 -824 (2011)
P11-10116 Ledermann JA, Hackshaw A, Kay e S, Jay son G, Gabra H, McNeish I, Earl H, 
Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin 
G.  Randomized phase II placebo -controlled trial of maintenance therap y using 
the oral triple angi okinase inhibitor BIBF 1120 after chemotherapy  for 
relapsed ovarian cancer.   45th Ann Mtg of the American Societ y of Clinical 
Oncology (ASCO), Orlando, 29 May  -2 Jun 2009 J Clin Oncol 29 (28), 
379838 (2011)
P11-11216 Richeldi L , Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, 
Brown KK, Flahert y KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, 
Klueglich M, Bois RM du Efficacy  of a t yrosine kinase inhibitor in idiopathic 
pulmonary  fibrosis. N Engl J Med 365 (12), 1079 - 1087 (2011)
P12-03241 King TE, Pardo A, Selman M Idiopathic pulmonary  fibrosis.Lancet 378
(9807), 1949 -1961 (2011)
P12-06085 Idiopathic Pulmonary  Fibrosis Clinical Research Network Prednisone, 
azathioprine, and N -acety lcysteine for pulmonary fibrosis. N En gl J Med 366 
(21), 1968 -1977 (2012)
P13-06268 Eisen T, Shpary k Y, Jones R, MacLeod NJ, Temple G, Finnigan H, Kaiser R, 
Studeny  M, Loembe AB, Bondarenko I Phase II efficacy  and safet y study of 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 76of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015nintedanib versus sunitinib in previously  untreated renal cell carcinoma (RCC) 
patients. 49th Ann Mtg of the Americ an Societ y of Clinical Oncology.
(ASCO), Chicago, 31 May  -4 Jun 2013 J Clin Oncol 31 (Suppl),, Abstr 4506 
(2013)
P13-12693 Yen CJ, Kim TY, Feng YS, Chao Y, L in DY, Studeny  M, Hocke J, Huang 
DCL ,Ryoo BY, Cheng AL Efficacy  and safet y of nintedanib versus sorafenib 
in Asian patients with advanced hepatocellular carcinoma: a randomised phase 
II trial. 38th Ann Cong of the European Societ y for Medical Oncology 
(ESMO), Amsterdam, 27 Sep - 1 Oct 2013 (Poster) 
P14-02860 Wollin L , Maillet I, Quesniaux V, Holweg A, R yffel B Anti- fibrotic and anti -
inflammatory  activity  of the ty rosine kinase inhibitor, nintedanib, in 
experimental models of lung fibrosis. J Pharmacol Exp Ther 349, 209 - 220 
(2014)
P14-07514 Richeldi L , et al, INPULSI S Trial Investigators . Efficacy  and safet y of 
nintedanib in idiopathic pulmonary  fibrosis. N Engl J Med 370 (22), 2071 -
2082 (2014)
P14-07665 Idiopathic Pulmonary  Fibrosis Clinical Research Network Randomized trial of 
acetylcysteine in idiopathic pulmonary  fibrosis. N Engl J Med 370 (22), 2093 -
2101 (2014)
P14-08020 Scagliotti GV, Leighl NB, Nowak AK, Pavlakis N, Popat S, Sorensen JB, 
Barrueco J, Kaiser R, Loembe AB, Mueller M, Wangenheim U von, Reck M
Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for 
unresectable malignant pleural mesothelioma (MPM): an international, 
multicenter, randomized, double- blind, placebo -controlled phase II stud y.
50th Ann Mtg of the American Societ y of Clinical Oncology (ASCO), 
Chicago, 30 May  -3 Jun 2014
R14-1149 Schmidt SL , Nambiar AM, Tay ob N, Sundaram B, Han MK, Gross BH,
Kazerooni EA, Chughtai AR, L agstein A, My ers JL, Murray  S, Toews GB, 
Martinez FJ, Flahert y KR . Pulmonary  function measures predict mortalit y 
differentl y in IPF versus combined pulmonary  fibrosis and emphy sema. Eur 
Respir J 38 (1), 176 -183 (2011)
P14-16496 Wuy ts WA, Antoniou KM, Borenszta jn K, Costabel U, Cottin V, Crestani B, 
Grutters JC, Maher TM, Poletti V, Richeldi L , Vancheri C, Wells AU
Combination therapy : the future of management for idiopathic pulmonary  
fibrosis? Lancet Respir Med 2, 933 -942 (2014)
P14-17347 Ogura T, Tani guchi H, Azuma A, I noue Y, Kondoh Y, Hasegawa Y, Bando 
M, Abe S, Mochizuki Y, Chida K, Klueglich M, Fujimoto T, Okazaki K, 
Taday asu Y, Sakamoto W, Sugiy ama Y . Safet y and pharmacokinetics of 
nintedanib and irfenidone in idiopathic pulmonary fibrosis .Eur Respir J, 
(2014)
P15-01243 Spagnolo P, Wells AU, Collard HR . Pharmacological treatment of idiopathic 
pulmonary  fibrosis: an update. Drug Discov Today , (2015)
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 77of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015P15-07362 Raghu G, et al, ATS, ERS, JRS, and AL AT. An official ATS/ERS/JRS/ALAT 
clinical practice guideline: treatment of idiopathic pulmonary  fibrosis: 
executive summary : an update of the 2011 clinical practice guideline. Am J 
Respir Crit Care Med 192 (2), 238 -248 (2015)
P15-08362 Raghu G, et al, ATS, ERS, JRS, and AL AT
An official ATS/ERS/JRS/AL AT clinical practice guideline: treatment of 
idiopathic pulmonary  fibrosis: executive summary: an update of the 2011 
clinical practice guideline.
Am J Respir Crit Care Med 192 (2), 238 -248 (2015)
P15-09876 Crestani B, Ogura T, Pelling K, Coeck C, Quaresma M, Kreuter M, Kay e M.
Interim anal ysis of nintedanib in an open -label extension of the INPUL SIS 
trials (INPUL SIS-ON). Eur Respir J 46 (Suppl 59), (2015)
P15-09946 Maher TM, Flaherty  KR, Noble PW, Vancheri C, Wuy ts WA, Kimura T, 
Hallmann C , Stowasser S, Richeldi L . Effect of baseline FVC on lung function 
decline with nintedanib in patients with I PF. Eur Respir J 46 (Suppl 59), 
(2015)
R06-2002 Macinty re N, Crapo RO, Viegi G, Johnson DC, Grinten CPM van der, 
Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, 
Hankinson J, Jensen R, McKay  R, Miller MR, Navajas D, Pedersen OF, 
Pellegrino R, Wanger J. Standardisation of the single -breath determination of 
carbon monoxide uptake in the lung. Eur Respir J 26 (4), 720 - 735 (2005)
R06-2070 Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai 
S, Itoh H, Ohi M, Sato A, Kudoh S, Research Group for Diffuse Lung 
Diseases in Japan, Raghu G Double -blind, placebo -controlled trial of 
pirfenidone in patients with idiopathic pulmonary  fibrosis.Am J Respir Crit 
Care Med 171, 1040 –1047 (2005)
R06-4126 Latsi PI, Bois RM du, Nicholson AG, Colby  TV, Bisirtzoglou D, 
Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic 
idiopathic interstitial pneumonia: the prognostic value of longitudinal 
functional trends. Am J Respir Crit Care Med 168, 531 -537 (2003)
R06-4127 Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK
Changes in clinical and phy siologic variables predict survival in idiopathic 
pulmonary  fibrosis.Am J Respir Crit Care Med 168, 538 -542 (2003)
R10-4316 Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, 
Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T,
Pirfenidone Clinical Study  Group in Japan . Pirfenidone in idiopathic 
pulmonary fibrosis. Eur Respir J 35 (4), 821 -829 (2010)
R10-4848 Common terminology  criteria for adverse events (CTCAE): version 4.0 (NIH 
publication no. 09- 5410, published: May  28, 2009 (v4.03 : June 14, 2010), 
revised June 2010, reprinted June 2010).
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 78of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_8.5x11.pd f (2010)
R10-6378 Yokoy ama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura 
M, Bando M, Sugiy ama Y, Tota ni Y, Ishizaki T, Ichiy asu H, Suga M, Hamada 
H, Kohno N. Prognostic value of circulating KL -6 inidiopathic pulmonary  
fibrosis. Respirology  11, 164 -168 (2006)
R10-6539 Flahert y KR, Mumford JA, Murray  S, Kazerooni EA, Gross BH, Colby  TV, 
Travis WD, Flint A, Toews GB, Ly nch JP, Martinez FJ . Prognostic 
implications of phy siologic and radiographic changes in idiopathic interstitial 
pneumonia. Am J Respir Crit Care Med 168, 543 -548 (2003)
R11-4827 Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, K ardatzke D, 
King TE, Lancaster L, Sahn SA, Szwarcberg J, Valey re D, Bois RM du, 
CAPACI TY Study  Group . Pirfenidone in patients with idiopathic pulmonary  
fibrosis (CAPACI TY): two randomised trials. Lancet 377, 1760 -1769 (2011)
R11-5086 Thabut G, Ch ristie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, Fournier M, 
Leseche G, Porcher R, Mal HSurvival after bilateral versus single -lung
transplantation for idiopathic pulmonary  fibrosis. Ann Intern Med 151 (11), 
767 - 774 (2009)
R12-2785 Keating D, Levvey  B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell 
G. Lung transplanation in pulmonary  fibrosis: challenging earl y outcomes 
counterbalanced b y surprisingly  good outcomes bey ond 15 y ears. Transplant 
Proc 41, 289 -291 (2009)
R12-2786 Kim DS, Collard HR, King TE Classification and natural history  of the 
idiopathic interstitial pneumonias. Proc Am Thorac Soc 3, 285 - 292 (2006)
R12-3474 Kotloff RM, Thabut G Lung transplantation. Am J Respir Crit Care Med 184, 
159 - 171 (2011)
R12-3676 McCurry  KR, Shearon TH, Edwards LB, Chan KM, Sweet SC, Valapour M, 
Yusen R, Murray  S, Lung transplantation in the United States, 1998 - 2007. 
Am J Transplant 9, 942 -958 (2009)
R12-3686 Idiopathic Pulmonary  Fibrosis Clinical Research Network. A controlled trial 
of sildenafil in advanced idiopathic pulmonary  fibrosis. N Engl J Med 363 (7), 
620 - 628 (2010)
R14-1149 Schmidt SL , et al. Pulmonary  function measures predict mortality  differently  
in IPF versus combined pulmonary  fibrosis an d emphy sema. Eur Respir J 38, 
176–183 (2011)
R14-2103 King TE, Bradford WZ, Castro -Bernardini S, Fagan EA, Glaspole I, Glassberg 
MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L , Lederer DJ, Nathan 
SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study  
Group A phase 3 trial of pirfenidone in patients with idiopathic pulmonary  
fibrosis. N Engl J Med 370 (22), 2083 -2092 (2014)
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 79of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015R15-1220 Jenkins RG, Simpson JK, Saini G, Bentley  JH, Russell AM, Bray brooke R, 
Moly neaux PL , McKeever TM, Wells A U, Fl ynn A, Hubbard RB, Leeming 
DJ, Marshall RP, Karsdal MA, L ukey  PT, Maher TM . Longitudinal change in 
collagen degradation biomarkers in idiopathic pulmonary  fibrosis: an anal ysis 
from the prospective, multicentre PROFILE stud y.Lancet Respir Med, (2015 )
R15-4125 Greene KE, King TE, Kuroki Y, Bucher -Bartelson B, Hunninghake GW, 
Newman LS, Nagae H, Mason RJ. Serum surfactant proteins -A and -D as
biomarkers in idiopathic pulmonary  fibrosis. Eur Respir J 19 (3), 439 - 446 
(2002)
R15-4126 Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, 
Li K, Choi J, Vuga L J, Lindell KO, Klesen M, Zhang Y, Gibson KF
Peripheral blood proteins predict mortality  in idiopathic pulmonary  fibrosis.
Am J Respir Crit Care Med 185 (1), 67 - 76 (2012)
R94-
1408 Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC.
Lung volumes and forced ventilatory  flows.Report Working Part y
Standardization of L ung Function Tests, European Community  for Steel and
Coal. Official Statement of t he European Respiratory  Societ y. Eur Respir J
1993 ;6 (Suppl 16): 5 -40.
R96-0690 Cockcroft DW, Gault MH . Prediction of creatinine clearance from serum 
creatinine. Nephron 16 (1), 31 -41 (1976)
UNPUBLISHED REFERENC ES 9.2
c01805141 -17Investigator’s brochure: BIBF 1120, Indication: Idiopathic pulmon ary 
Fibrosis. 1199.P3. Version 10. 23 Sep 2015 .
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 80of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan201510. APPENDICES
CRITERIA FOR HRCT/BIOPSY CENTRAL 10.1
All chest HRCTs, and histopathology  slides of surgical lung bi opsies (the latter if available) 
will be centrall y reviewed.
In the absence of a surgical lung biops y, chest HRCT must qualify  as “consistent with UI P”.
This will be defined as meeting either criteria A, B and C, or criteria A and C, or criteria B 
and C be low. 
A)      Definite honey comb lung destruction with basal and peripheral predominance.
B)      Presence of reticular abnormality  AND traction bronchiectasis consistent with fibrosis 
with basal and peripheral predominance. 
C)      Aty pical features are ABSENT, specificall y: nodules and consolidation. Ground glass 
opacity , if present, is less extensive than reticular opacity pattern.
Appearances of a fibrosing lung disease with no definite HRCT features of a specific etiology  
will be considered “possible IPF”. Convincing HRCT appearances of a diffuse lung disease 
other than IPF will be considered “definitely  not IPF”. “Possible I PF” and “definitel y not 
IPF” will not be allowed for inclusion in the trial.
In the presence of a surgical lung biops y, the histo logy will be reviewed based on the 
ATS/ERS/JRS/AL AT guidelines [ P11-07084 ]. In such case, there will be a multi -disciplinary  
team approa ch (radiologist and pathologist ) to confirm or exclude the diagnosis of I PF. An 
HRCT "possi ble IPF" coupled with a surgical biopsy  of “definite UI P” or "probable UIP", 
upon multidisciplinary  team discussion, could qualify  for inclusion as “consistent with I PF”.
CREATININE CLEARANCE 10.2
Creatinine clearance calculation is done according to Cockroft and Gault [ R96-0690 ].
Creatinine clearance = (140 - age) x (Weight in kg) x (0.85 if female) / (72 x serum creatinine 
in mg/dL)
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 81of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 82of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 83of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 84of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 85of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 86of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 87of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 88of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 89of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 90of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 91of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015DLCO 10.5
For predicted normal values, different sites may  use different prediction formulas, based on 
the method used to measure DLCO. In an y case, the method used must be in compliance with 
the ATS/ERS guideline on DL CO measurements [R06 -2002 ], and the prediction formula 
appropriate for that method. Raw data (gas mixture, equation used for prediction of normal, 
further adjustments made if so) must be traced.
Predicted DLCO cor rected for haemoglobin (Hb) expressed in g x dL-1(R06- 2002) can be 
calculated as:
Predicted DLCO corrected for Hb = Predicted DLCO x (1.7Hb/(10.22+Hb)) for males 
aged 15 years or above
Predicted DLCO corrected for Hb = Predicted DLCO x (1.7Hb/(9.38+Hb)) for 
females and children aged less than 15 y ears
DLCO results from Visit 1 will be corrected for haemoglobin (value obtained at Visit 1) by  
the site. 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 92of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan201511. DESCRIPTION OF GLOBA L AMENDMENT(S)
Number of global amendment 1
Date of CTP revision 23February  2016
EudraCT number 2015-003148-38
BI Trial number 1199.227
BI Investigational Product(s) nintedanib
Title of protocol A 12 -week, double blind, randomised, placebo 
controlled, parallel group trial followed by  a single 
active arm phase of 40 weeks evaluating the effect 
of oral nintedanib 150 mg twice dail y on change in 
biomarkers of extracellular matr ix (ECM) turnover 
in patients with idiopathic pulmonary  fibrosis (IPF) 
and limited forced vital capacit y (FVC) 
impairment.
To be implemented only after 
approval of the IRB /IEC /
Competent Authorities
To be implemented immediately 
in order to eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
change with request for 
approval
Can be implemented without 
IRB /IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects only
Section to be changed No content changes
Description of change The document numbe r on title page and headers 
waswrong .
Rationale for change Not Applicable
Number of global amendment 2
Date of CTP revision 25 February  2016
EudraCT number 2015-003148-38
BI Trial number 1199.227
BI Investigational Product(s) nintedanib
Title of protocol A 12 -week, double blind, randomised, placebo 
controlled, parallel group trial followed by  a single 
active arm phase of 40 weeks evaluating the effect 
of oral nintedanib 150 mg twice dail y on change in 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 93of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015biomarkers of extracellular matrix (ECM) turnover 
in patients with idiopathic pulmonary  fibrosis (IPF) 
and limited forced vital capacit y (FVC) 
impairment.
To be implemented only after 
approval of the IRB / IEC / 
Competent Authorities
To be implemented immediately 
in order to eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
change with request for 
approval
Can be implemented without 
IRB / IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects only
Section to be changed No content changes
Description of change Not Applicable
Rationale for change Technical error during signature workflow
Number of global amendment 3
Date of CTP revision 04 May  2017
EudraCT number 2015-003148-38
BI Trial number 1199.227
BI Investigational Product(s) nintedanib
Title of protocol A 12 -week, double blind, randomised, placebo 
controlled, parallel group trial followed by  a single 
active arm phase of 40 weeks evaluating the effect 
of oral nintedanib 150 mg twice dail y on change in 
biomarkers of ext racellular matrix (ECM) turnover 
in patients with idiopathic pulmonary  fibrosis (IPF) 
and limited forced vital capacit y (FVC) 
impairment.
To be implemented only after 
approval of the IRB / IEC / 
Competent Authorities
To be implemented immediately 
in order to eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
change with request for 
approval
Can be implemented without 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 94of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015IRB / IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects only
Section to be changed
1.Flow Chart: Biomarker serum and plasma, 
RNA, PK and optional serum banking 
samples collections added
2.Explanatory  Note 2 on page 29, Old text 
“or”, new text “and/or”
3.Page 45 ,fingertip added as a possib ility to
perform measure ment of oxygen saturation
4. Further explanation added regarding visit 
planning and conduct on pages 56, 58 and 
62 
Description of change Change 1: correction of ty po, allow consistency  in 
procedures between visit 10 (EOT) and Earl y EOT
Change 2 and 3: correction of ty pos, maintain 
consistency  within the clinical project
Change 4: further clarification of visit planning and 
visit conduct
Rationale for change Correction of Ty pos, additional clarification and 
explanation of trial related procedures, align 
procedures wi thin the clinical project
Number of global amendment 4
Date of CTP revision 09 July 2018
EudraCT number 2015-003148-38
BI Trial number 1199.227
BI Investigational Product(s) nintedanib
Title of protocol A 12 -week, double blind, randomised, placebo 
controlled, parallel group trial followed by  a single 
active arm phase of 40 weeks evaluating the effect 
of oral nintedanib 150 mg twice dail y on change in 
biomarkers of extracellular matrix (ECM) turnover 
in pa tients with idiopathic pulmonary  fibrosis (IPF) 
and limited forced vital capacit y (FVC) 
impairment.
To be implemented only after 
approval of the IRB / IEC / 
Competent Authorities
To be implemented immediately 
in order to eliminate hazard –
IRB / IEC / Competent 
Boehringer Ingelheim 09 Jul 2018
BI Trial No.: 1199.227
c03495745 -05 Trial Protocol Page 95of 95
Proprietary confidential information © 2018 Boehringer I ngelheim International GmbH or one or more of its affiliated companies
001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015Authority to be notified of 
change with request for 
approval
Can be implemented without 
IRB / IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects only
Section to be changed 5.1.3
Description of change  
 
 
 
Rationale for change
Section to be changed
Description of change
Rationale for change
 

   
 
APPROVAL / SIGNATURE PAGE 
 Document Number:  Technical Version Number:  
Document Name:  
  
                                                                                                                  
Title:  
 
 
 
                                                                                                                    
Signatures (obtained electronically) 
 
Meaning of Signature  Signed by Date Signed 
 
  
  
   
 
  
  
   
 
   
   
 
  
  
   
 
   
   
 
  
  
   
 
  
  
   
 
  
  
 c03495745 5.0
clinical-trial-protocol-version-5
A 12-week, double blind, randomised, placebo controlled, parallel group trial
followed by a single active arm phase of 40 weeks evaluating the effect of oralnintedanib 150 mg twice daily on change in biomarkers of extracellular matrix(ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limitedforced vital capacity (FVC) impairment.
Author-Trial Clinical
Pharmacokineticist10 Jul 2018 10:32 CEST
Author-Trial Clinical Monitor 10 Jul 2018 10:37 CEST
Approval-Team Member MedicalAffairs10 Jul 2018 10:50 CEST
Author-Trial Statistician 10 Jul 2018 16:25 CEST
Approval-Therapeutic Area 16 Jul 2018 10:42 CEST
Verification-Paper SignatureCompletion16 Jul 2018 10:46 CEST

Boehringer Ingelheim Page  2 of 2
Document Number:  Technical Version Number :  
 
 (Continued) Signatures (obtained electronically) 
 
Meaning of Signature  Signed by Date Signed 
 
   
  
 
 
  
  
  
 
  
 
    
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 c03495745 5.0